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Acetaminophen (APAP) is a threshold hepatotoxicant whose overdose 
produces a fulminant hepatic necrosis. Therapeutic doses are non-hepatotoxic 
but high therapeutic dosing may induce hepatotoxicity in some vulnerable 
patients. The underlying mechanism of APAP hepatotoxicity involves 
mitochondrial dysfunction, including respiratory inhibition, mitochondrial oxidant 
stress, onset of the mitochondrial permeability transition (MPT) and loss of the 
mitochondrial membrane potential (ΔΨ). Iron-mediated reactive oxygen species 
(ROS) formation is essential in oxidative stress. Previous studies show that iron 
released from lysosomes is taken up into mitochondria during APAP 
hepatotoxicity, which triggers the MPT and cell killing. Here, my aim was to 
investigate mitochondrial mechanisms and the role of iron in hepatotoxicity in 
vitro and in vivo after various doses of APAP. Mouse hepatocytes and C57BL/6 
mice were administered APAP in the presence and absence of NIM811 (MPT 
inhibitor), starch-desferal (lysosomally targeted iron chelator), Ru360 and 
minocycline (inhibitors of the mitochondrial Ca,Fe uniporter [MCFU], or N-
acetylcysteine (NAC, an antioxidant). Necrotic cell killing was determined by 
propidium iodide (PI) fluorometry. Chelatable Fe2+, mitochondrial membrane 
potential and ROS were monitored by confocal/ multiphoton microscopy of 
different fluorophores. Liver injury was assessed by ALT release and liver 
necrosis. In vivo studies showed that high dose APAP (300 mg/kg) caused ALT 
release, liver necrosis, irreversible mitochondrial dysfunction and cell death. By 
contrast, low dose APAP causes reversible mitochondrial dysfunction associated 
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with transient JNK activation and translocation to mitochondria of hepatocytes 
without ALT release or necrosis in vivo.  NIM811 attenuated these changes at 
both low and high APAP, indicating that the MPT is the likely principal 
mechanism of mitochondrial dysfunction.  
In searching for the upstream inducer of MPT that may participate in APAP 
hepatotoxicity, we examined the role of iron. After exposure of hepatocytes to 
APAP, confocal/multiphoton microscopy showed that iron translocates from 
lysosomes into mitochondria both in vitro and in vivo. Mitochondria take up this 
Fe2+ via the mitochondrial MCFU to trigger formation of reactive oxygen species 
(ROS) and the MPT. The iron chelator, starch-desferal, and the MCFU inhibitors, 
Ru360 and minocycline, protected against APAP-induced liver injury. In addition, 
minocycline post-treatment at 4 h after APAP showed protection in vivo, whereas 
NAC was ineffective at this late time point. Taken together, the data suggest that 
release of chelatable Fe2+ from lysosomes followed by uptake into mitochondria 
via MCFU occurs during APAP hepatotoxicity, which in turn catalyzes ROS 
formation and triggers iron-dependent MPT and cell killing. The efficacy of 
minocycline posttreatment compared to NAC shows minocycline as a new 















1.1 Epidemiology of Acetaminophen (APAP) hepatotoxicity 
Acetaminophen (APAP, also known as Tylenol®, paracetamol, and N-
acetyl-p-aminophenol) is one of the most commonly used antipyretic and 
analgesic medications and is often combined with cough-and-cold remedies and 
narcotic pain relievers. APAP is believed to be safe at therapeutic doses. 
However, overdose of APAP causes severe liver injury, including serum alanine 
aminotransferase (ALT) elevation, hepatic necrosis and even acute liver failure (1, 
2). APAP hepatotoxicity is the leading cause of acute liver failure in the United 
States and up to 50% of cases are unintentional (3). The currently recommended 
maximal therapeutic dose is 4 g/day. However, it is estimated that 6% of adults in 
the USA are taking over 4 g/day due to APAP combination medications (4). 
Accordingly, the US Food and Drug Administration (FDA) is considering a 
reduction of the maximum daily dose a 4 g/day and a prohibition of combination 
products with more than 325 mg of APAP per tablet (4). 
 
1.2 Metabolism of APAP 
At therapeutic doses in humans, 85-90% of APAP becomes conjugated 
with sulfate and glucuronide and is excreted in urine (Fig. 1-1). Only a small 
portion of APAP is metabolically activated by cytochrome P450 (mainly CYP2E1) 
enzymes to the toxic reactive metabolite, N-acetyl-p-benzoquinoneimine (NAPQI). 
Under normal conditions, NAPQI is efficiently detoxified by conjugation with 
glutathione (GSH) (5). After overdose of APAP, the sulfate and glucuronide 
pathways become saturated and CYP450 produces relatively more NAPQI. 
3 
 
Subsequently, GSH becomes depleted by conjugation with NAPQI, which then 
leads to liver damage (1, 6). 
 
1.3 Risk factors of APAP hepatotoxicity 
APAP toxicity shows a threshold dose-dependence such that therapeutic 
doses are completely non-toxic, but the threshold dose causing liver damage 
varies between individuals. Not all individuals with APAP overdose progress to 
acute liver failure. Moreover even at a therapeutic dose, APAP hepatotoxicity can 
occur in certain conditions. Accordingly, the safe upper limit of APAP for 
therapeutic indications remains controversial (7-9). Genetic variation within the 
CYP450 system can cause differing sensitivity to APAP hepatotoxicity, as well as 
other risk factors for APAP hepatotoxicity (10, 11). 
 
Malnutrition, fasting and chronic liver disease may increase the risk of 
APAP hepatotoxicity by decreasing hepatic levels of GSH. A 6 h fast depletes 
hepatic GSH levels in mice by 44% (12). Patients with already low GSH stores as 
a result of fasting or malnutrition can develop severe hepatotoxicity at 
recommended doses of APAP (13). Infants and adults who are alcoholic or 
taking certain CYP450-inducing drugs may also be more prone to liver injury 
from APAP (9, 14, 15). Commonly used upregulating CYP450 drugs include 
rifampin, isoniazid and phenobarbital. Chronic alcohol use also causes CYP 450 
enzyme induction with increased toxic metabolic activation of APAP and 
enhanced hepatotoxicity even at lower-than-therapeutic doses. Fibrates, 
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nonsteroidal anti-inflammatory drugs (NSAIDs) and alcohol are associated with a 
high incidence of death in patients with APAP-associated liver injury (11). Recent 
studies have found that nonalcoholic fatty liver disease (NAFLD) is associated 
with increased CYP2E1 activity and accompanied by increased risk of APAP-
induced hepatotoxicity (2). 
 
1.4 Pathogenesis of APAP hepatotoxicity 
The toxic metabolite NAPQI rather than APAP itself causes hepatotoxicity. 
The main mechanisms causing liver injury are thought to include covalent NAPQI 
protein adduct formation, which leads to mitochondrial dysfunction, oxidative 
stress due to GSH depletion by conjugation with NAPQI and cell death. 
 
Mitochondria are a primary target of NAPQI. Mitochondrial protein adduct 
formation with NAPQI causes oxidative stress, which leads to various 
mitochondrial dysfunctions, including respiratory inhibition, decreased hepatic 
ATP, decreased mitochondrial membrane potential (ΔΨ) and onset of the 
mitochondrial permeability transition (MPT) (16, 17).  The MPT is an abrupt 
increase in the permeability of the mitochondrial inner membrane to molecules of 
less than about 1500 Daltons in molecular weight (18). In one model, PT pores 
are formed by the voltage dependent anion channel in the outer membrane, the 
adenine nucleotide translocator in the inner membrane, and cyclophilin D in the 
matrix. However, genetic deficiency of ANT and VDAC does not prevent onset of 
the MPT (19-21). More recent studies suggest that the oligomycin sensitivity-
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conferring protein subunit of the mitochondrial F1Fo-ATPase is a component of 
PT pores (22, 23). In addition, two conductance modes for the PT pore have 
been reported: one activated by Ca2+ and inhibited by CsA and Mg2+ and the 
other unregulated. Previous studies in our laboratory proposed a new model of 
pore formation and gating in which PT pores form by aggregation of misfolded 
integral membrane proteins damaged by oxidant and other stresses. Chaperone-
like proteins initially block conductance through these misfolded protein clusters; 
however, increased Ca2+ opens these regulated PT pores, an effect blocked by 
CsA. When protein clusters exceed chaperones available to block conductance, 
unregulated pore opening occurs (24). Overall, the precise molecular 
composition of PT pore remains unclear.  
 
Cyclosporin A (CsA) specifically blocks MPT by binding to cyclophilin D. 
NIM811 (N-methyl-4-isoleucine cyclosporin) is a non-immunosuppressive 
derivative of CsA that inhibits the MPT equivalently to CsA in isolated 
mitochondria. NIM811 is protective to cultured hepatocytes and livers in vivo 
grafts after a variety of injurious stresses, including ischemia/reperfusion injury, 
transplantation, massive hepatectomy and cholestatic injury (25-29). Previous 
studies indicate that cyclosporin A (CsA) inhibits the MPT and attenuates APAP 
hepatotoxicity both in vivo and in vitro (16, 30, 31).  PT pores have two open 
conductance modes - a Ca2+-activated and CsA-sensitive regulated mode 
associated with early PT pore opening and an unregulated mode occurring later, 
which does not require Ca2+ and is not inhibited by CsA (24). In cultured mouse 
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hepatocytes, CsA and NIM811 delayed but did not prevent APAP-induced 
mitochondrial depolarization, indicating APAP initially induces a regulated MPT 
that is later superseceded by an unregulated MPT (16). Ultimately, the release of 
proapoptotic mitochondrial proteins together with the cessation of ATP 
production leads to cell death (32). 
 
Whether apoptosis or necrosis is the major mode of cell death in APAP 
hepatotoxicity has been a controversial topic. The MPT plays an important role in 
development of both necrotic and apoptotic cell death (33). Specifically, 
uncoupling of oxidative phosphorylation after the MPT causes ATP depletion, 
which leads to necrotic cell killing, whereas mitochondrial outer membrane 
rupture after MPT-induced mitochondrial swelling causes cytochrome c release 
and apoptosis. In vitro, APAP mainly induces necrosis in cultured mouse 
hepatocytes, however apoptosis increases when necrotic cell death is blocked 
(34). Animal studies suggested that APAP-induced hepatic damage is 
predominantly oncotic necrosis rather than apoptosis (35). Although modest 
caspase activation resulting from the release of mitochondrial proteins may occur 
after APAP, it is insufficient to actually cause significant apoptotic cell death (36). 
Nonetheless, a recent human study reported increased serum apoptotic markers 
in patients with APAP-induced acute liver failure and suggested a predictive role 





Oxidative stress is a principal mediator of toxicity and has been suggested 
as an important mechanism in APAP-induced hepatotoxicity. Formation of 
reactive oxygen species (ROS) increases after APAP exposure, and agents that 
augment antioxidant defenses and scavenge ROS protect against APAP toxicity 
in vitro and in vivo (38). It has been recognized that ROS formation occurs 
selectively in mitochondria after the initial metabolism of APAP (39, 40). The Iron-
catalyzed Fenton reaction is critical in oxidative stress in APAP toxicity (Fig. 1-2). 
Initially, cellular superoxide may be formed by activated NADPH oxidase, 
uncoupled CYP2E1 or mitochondrial uncoupling of the electron transport chain 
(ETC). Dismutation catalyzed by superoxide dismutase (SOD) converts 
superoxide to hydrogen peroxide (H2O2). After overdose APAP, H2O2 cannot be 
completely detoxified by glutathione peroxidase since its cofactor, GSH is 
depleted by NAPQI. Superoxide also reduces ferric iron (Fe3+) to ferrous iron 
(Fe2+), which in turn causes chemical reduction of H2O2 to the highly reactive 
hydroxyl radical (OH•). OH• in turn causes protein and lipid peroxidation, 
breakdown of membranes and mitochondrial DNA (mtDNA) damage. However, 
the most critical effect of this oxidative stress is induction of the MPT, which 
produces an even larger increase of oxidative stress and ultimately cell death. 
Nitric oxide also reacts with superoxide to form reactive and toxic peroxynitrite, 
which leads to nitrosative stress in APAP toxicity. The iron chelator, desferal, 
inhibits hepatotoxicity, whereas addition of iron back to the incubation medium 




1.5 Treatment for APAP hepatotoxicity 
Early diagnosis means early intervention, which is crucial to prevent APAP-
induced acute liver failure (ALF). N-acetylcysteine (NAC) is the preferred antidote 
for APAP toxicity. NAC prevents the hepatotoxicity of APAP by replenishing GSH 
stores, binding with NAPQI and enhancing sulfate conjugation (44). NAC may 
further limit APAP toxicity by antioxidant and anti-inflammatory effects. For 
maximal protection against liver injury, NAC should be given within 8 h after 
overdose APAP in patients whose plasma APAP levels are above the “possible 
hepatic toxicity” line of the Rumack-Matthew nomogram (Fig. 1-3) (1, 45). NAC 
can be given intravenously or by mouth with similar efficacy of improving 
outcomes in APAP overdose. However, the indications and dosage for NAC are 
debated. Other treatments include activated charcoal and liver transplantation. 
Activated charcoal can be used within 4 h after taking APAP to limit 
gastrointestinal absorption of APAP. However this treatment is ineffective in most 
cases because of the rapid absorption of APAP. Liver transplantation is the 
ultimate treatment for patients with ALF. 
 
1.6 Iron metabolism 
Iron is essential in the catalysis of enzymatic reactions that involve electron 
transfer and plays a critical role for cellular survival. However, free iron is toxic 
due to its ability to generate free radicals via Fenton reaction. Thus, control of 
this necessary but potentially toxic metal is important for human health and 
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disease. Iron homeostasis is tightly controlled by the regulation of its import, 
storage and efflux (46, 47) 
 
1.6.1 Cellular iron metabolism 
In animal cells, non-heme iron may be transported into cells through two 
main pathways: transferrin (Tf)-bound iron uptake and non-Tf-bound iron (NTBI) 
uptake (Fig. 1-4). NTBI uptake occurs when the body absorbs dietary iron from 
intestinal lumen or Tf becomes saturated with iron because of iron overload. 
Although the exact NTBI uptake pathway is unclear, it has been proposed that 
ferric NTBI is required to be reduced by reductases such as duodenal 
cytochrome b (Dcytb) to ferrous iron, which is imported into cells via divalent 
metal transporter 1 (DMT1) or the ZRT/IRT-like proteins (ZIPs) (48-50). 
 
Under physiological conditions, almost all serum iron is bound to Tf. Uptake 
of Tf-bound iron through the Tf receptor (TfR1) is the major pathway for delivery 
of iron into cells (46, 47). Tf-dependent iron delivery begins with binding of 
diferric Tf to TfR1 on the cell surface and endocytosis of the Tf-TfR1 complexes. 
As pH decreases during endosome maturation and fusion with lysosomes, ferric 
iron dissociates from the Tf and both Tf and TfR1 recycle to the cell surface for 
another round of iron uptake. A ferrireductase (Steap3) then reduces dissociated 
Fe3+ to Fe2+ by within the endosomal/lysosomal compartment. Fe2+ subsequently 
exits the endosomal/lysosomal compartment into the cytosol via DMT1 or ZIP14 
(51, 52). This translocation of iron may also be mediated by an Fe2+/H+ exchange 
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mechanism in endosomal/lysosomal membranes (53). Cytosolic iron is released 
in a soluble, chelatable state, which constitutes the labile iron pool (LIP). From 
this pool, iron can be stored in ferritin, utilized for metabolism (e.g., imported into 
mitochondria for the synthesis of heme and Fe-S clusters [ISC]), used to 
generate ROS or exported from the cell by ferroportin 1 (FPN1) (47, 48). 
Interestingly, lysosomes may also be involved in iron storage because of the 
degradation of many macromolecules containing iron inside lysosome (54). 
 
1.6.2 Mitochondrial iron metabolism 
Mitochondria primarily utilize iron for synthesis of heme and ISC (55, 56). 
Iron moves into mitochondria membrane by the following hypothesized 
mechanisms: (i) Iron-loaded endosomes/lysosomes interact directly with 
mitochondria by a “kiss-and-run” mechanism (57). (ii) Iron from ferritin transfers 
into mitochondria after ferritin complex degradation (58-60). These mechanisms 
are not well understood and need further testing. 
 
For the mitochondrial inner membrane, two mitochondrial transporters, the 
mitochondrial calcium ferrous iron uniporter (MCFU) and the two isoforms of 
mitoferrin (Mfrn1/2), play essential roles in transporting iron. MCFU catalyzes 
electrogenic mitochondrial uptake of both Ca2+ and Fe2+ and can be blocked by a 
specific MCFU inhibitor, Ru360 (61). Mfrn1 and its parolog Mfrn2 also mediate 
mitochondrial iron uptake in erythroid and non-erythroid cells, respectively (62, 
63). The loss of Mfrn1 and 2 leads to anemia and disruptions in ISC biogenesis 
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(62). More recently, it was discovered that Mfrn2 physically interacts with MCFU 
and appears to be a component/regulator of the MCFU complex (64). 
 
Once imported into the mitochondria, iron is utilized for the synthesis of 
heme and Fe-S clusters, which are important for mitochondrial respiratory 
enzymes, or stored in mitochondrial ferritin (FTMT). However, when superoxide 
(O2•
-) and H2O2 are generated from mitochondrial respiration and cannot be 
detoxified by antioxidant systems, Fe2+ in mitochondria may catalyze OH• 
formation via the Fenton reaction, leading to lipid peroxidation, mitochondrial 
dysfunction and tissue damage (65). Iron-dependent OH• formation has been 
implicated in various injuries, including hepatic injury, myocardial injury and 
neurological injury (66-68). APAP toxicity may also involve iron-mediated 
oxidative stress (69). Iron chelators that inhibit iron uptake and antioxidants that 
scavenge ROS protect against APAP toxicity in vitro and in vivo (38, 70, 71). 
 
Aim of the study 
The goal of this project was to study mitochondrial mechanisms of 
acetaminophen (APAP) hepatotoxicity. In this project, I investigated the role of 
the MPT in liver injury and mitochondrial dysfunction after different doses of 
APAP in vivo in mice. I then investigated the role of lysosomal iron moboilization 
and mitochondrial MCFU in mitochondrial dysfunction induced by APAP to 
cultured mouse hepatocytes using the lysosomally targeted iron chelator, starch-
desferal and the MCFU inhibitors, minocycline and Ru360. Finally, I assessed in 
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vivo protection by starch-desferal and minocycline against APAP toxicity. My aim 
was to determine the role of iron mobilization on oxidative stress and 








Figure. 1-1 Metabolism of APAP. Sources: US. Food and Drug 
Administration; National Institutes of Health; Medscape.com; Dr. Paul Watkins, 




































Low Dose Acetaminophen Induces Mitochondrial 





Acetaminophen (APAP) overdose causes acute hepatotoxicity, but the safe 
upper limit of APAP for patients is controversial. Here, our aim was to investigate 
whether doses of APAP normally considered non-toxic by the criterion of serum 
alanine aminotransferase (ALT) release and histological necrosis can 
nonetheless cause mitochondrial dysfunction in vivo. Male C57BL/6 mice were 
fasted overnight and then administered with vehicle or APAP (75, 150 and 300 
mg/kg, i.p.). NIM811 (10 mg/kg) or vehicle was gavaged 1 h before APAP. After 
75 and 150 mg/kg APAP, serum ALT and liver histology after 6 and 24 h were 
not different than after vehicle. However after 150 mg/kg APAP, intravital 
multiphoton microscopy revealed mitochondrial depolarization and fat droplet 
formation without cell death at 6 h, which resolved completely after 24 h. By 
contrast, 300 mg/kg APAP induced ALT release, hepatic necrosis, mitochondrial 
depolarization and cell death in pericentral hepatocytes after 6 h, becoming more 
severe after 24 h. Mitochondrial protein N-acetyl-p-benzoquinone imine (NAPQI) 
adducts correlated with early JNK activation, but irreversible mitochondrial 
depolarization and cell necrosis at high dose were associated with sustained JNK 
activation and translocation to mitochondria. The inhibitor of the mitochondrial 
permeability transition (MPT), NIM811, prevented mitochondrial depolarization 
completely after 150 mg/kg APAP and decreased both depolarization and cell 
death after 300 mg/kg APAP. In conclusion, low dose APAP can produce 
reversible mitochondrial dysfunction and steatosis in hepatocytes without causing 
ALT release or necrosis in vivo. Sustained JNK activation fails to occur at lower 
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dose, which may explain the reversibility of injury. NIM811 attenuates APAP-
induced changes, indicating that the MPT is the likely mechanism of in vivo 
mitochondrial dysfunction. Thus, otherwise non-toxic dosages of APAP have the 
potential to cause transient mitochondrial dysfunction that may synergize with 





Acetaminophen (APAP) overdose can cause severe liver injury, including 
serum alanine aminotransferase (ALT) elevation, hepatic necrosis and acute liver 
failure (44). APAP toxicity shows a threshold dose dependence such that 
therapeutic doses are generally considered non-toxic. The threshold dose 
causing liver damage varies between individuals. Infants and adults who are 
malnourished, alcoholic or taking certain CYP450-inducing drugs may have 
increased sensitivity to APAP hepatotoxicity (14, 75, 76). The safe upper limit of 
APAP for therapeutic indications is still controversial (7, 8).  
 
Although extensively studied, mechanisms of APAP-induced liver injury 
remain incompletely understood. Most of the drug is conjugated and excreted as 
glucuronide or sulfate conjugates, but a small portion of APAP is metabolically 
activated by cytochrome P450 (CYP450) enzymes to the toxic reactive 
metabolite, N-acetyl-p-benzoquinone imine (NAPQI) (6). NAPQI can be 
detoxified by glutathione but after an overdose excessive NAPQI binds to cellular 
proteins and initiates toxicity (6).  
 
APAP-induced liver cell damage in vitro and in vivo is predominantly oncotic 
necrosis rather than apoptosis (35). Mitochondria are a primary target of NAPQI 
(77). Previous studies show that APAP overdose causes mitochondrial 
dysfunction, including respiratory inhibition, mitochondrial oxidant stress, and 
onset of the mitochondrial permeability transition (MPT), leading to loss of the 
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mitochondrial membrane potential and decreased hepatic ATP levels (16, 17)).  
The MPT is an abrupt increase in the permeability of the mitochondrial inner 
membrane to molecules of less than about 1500 Daltons in molecular weight (18). 
The MPT plays an important role in development of both necrotic and apoptotic 
cell death (33). The initiation of the MPT after APAP is associated with activation 
of c-Jun N-terminal protein kinase (JNK) (17). A recent study shows that 
receptor-interacting proteins 1 also (RIPK1) participates in APAP-induced 
necrosis upstream of JNK activation (78).   
 
Previous studies indicate that cyclosporin A (CsA) inhibits the MPT and 
attenuates APAP hepatotoxicity both in vivo and in vitro (16, 30, 31).  NIM811 (N-
methyl-4-isoleucine cyclosporin) is a non-immunosuppressive derivative of CsA 
that inhibits the MPT equivalently to CsA in isolated mitochondria, cultured 
hepatocytes, and liver grafts after transplantation (25, 26). Because of 
controversies regarding the safe upper limit for APAP dosing, we investigated the 
possibility that APAP might cause MPT-dependent, NIM811-sensitive 
mitochondrial dysfunction at doses of APAP not causing overt hepatic damage. 
Using an in vivo mouse model of APAP hepatotoxicity and multiphoton 
microscopy, we show that APAP can cause reversible mitochondrial 
depolarization that is blocked by NIM811 at doses below the threshold causing 




MATERIALS AND METHODS 
 
Animals. Male C57BL/6 mice (8-9 weeks) were purchased from Jackson 
Laboratories (Bar Harbor, ME). The animals were fasted overnight and then 
treated with vehicle (warm saline) or APAP (75-300 mg/kg, i.p.). NIM811 
(Novartis, Basel, Switzerland; 10 mg/kg) or its vehicle (8% Cremophor EL 
[Sigma-Aldrich, St. Louis, MO], 8% ethanol in distilled water) was gavaged 1 h 
before APAP. Animal protocols were approved by the Institutional Animal Care 
and Use Committee. 
 
Alanine aminotransferase (ALT). At 6 and 24 h after vehicle or APAP 
injection, mice were anesthetized with ketamine/xylazine (100 mg/kg/, xylazine, 
i.p.), and blood was collected from the inferior vena cava. Serum ALT was 
measured using a commercial kit (Pointe Scientific, Canton, MI).  
 
Histology. Livers were fixed by immersion in 4% buffered 
paraformaldehyde. Area percent of necrosis was quantified in hematoxylin and 
eosin (H&E)-stained paraffin sections (IP Lab, BD Biosciences, Rockville, MD). 
To assess steatosis, livers were frozen, sectioned and stained with Oil-Red-O. 
 
Isolation of subcellular fractions and Western blotting. Mouse liver 
mitochondria and cytosolic fractions were isolated by differential centrifugation, 
as described (79). Western blotting was performed using rabbit anti-JNK and 
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anti-phospho-JNK (pJNK) antibodies (Cell Signaling Technology, Danvers, MA) 
(79). Mitochondrial protein adducts were measured using HPLC with 
electrochemical detection as described (80).  
 
Loading of fluorescent probes. At 6 and 24 h after vehicle or APAP 
injection, mice were anesthetized with ketamine/xylazine and connected to a 
small animal ventilator via a respiratory tube (20-gauge catheter) inserted into the 
trachea. Green-fluorescing rhodamine 123 (Rh123, 2 µmol/mouse, mitochondrial 
ΔΨ indicator (25, 81)]) plus red-fluorescing PI (0.4 µmol/mouse, cell death 
indicator (82)]) or green-fluorescing BODIPY493/503 (0.4 µmol/mouse, lipid 
labeling agent (83)]) plus red-fluorescing tetramethylrhodamine methylester 
(TMRM, 2 µmol/mouse, ΔΨ indicator (81)]) were infused via polyethylene-10 
tubing inserted into the femoral vein over 10 min.  
 
Intravital Multiphoton Microscopy. After infusion of fluorescent probes, 
individual mice were laparotomized and placed in a prone position. The liver was 
gently withdrawn from the abdominal cavity and placed over a #1.5 glass 
coverslip mounted on the stage of an inverted Olympus Fluoview 1000 MPE 
multiphoton microscope (Olympus, Center Valley, PA) equipped with a 25X 1.05 
NA water immersion objective lens and a Spectra Physics Mai Tai Deep Sea 
tunable multiphoton laser (Newport, Irvine, CA). Rh123 and PI fluorescence was 
imaged simultaneously using 820-nm multiphoton excitation. In other 
experiments, BODIPY and TMRM fluorescence was imaged using 920-nm 
24 
 
multiphoton excitation. During image acquisition, the respirator was turned off 5-
10 sec to eliminate breathing movement artifacts. In some experiments, z-stacks 
of green and red fluorescence images were collected from planes 5.0 µm apart. 
Unless otherwise stated, images were collected 25 µm from the liver surface. 
Pericentral areas were identified by the sinusoidal configuration. Images in 10 
random fields were analyzed using IP Lab. Nonviable PI-positive cells were also 
counted in 10 random fields per liver. 
 
Statistical Analysis. Data are presented as means ± standard error. 
Differences between groups were analyzed by Student’s t test using P < 0.05 as 





High but not low APAP causes macroscopic liver injury and ALT release 
that is inhibited by NIM811  
After vehicle treatment at 6 and 24 h, gross liver appearance was normal 
and indistinguishable from untreated mice. After 300 mg/kg APAP, livers became 
pale and mottled at 6 h with frank hemorrhage at 24 h. However after 150 mg/kg 
APAP with and without NIM811 pretreatment, gross liver appearance was not 
different from vehicle at both 6 and 24 h. NIM811 pretreatment decreased gross 
liver injury after 300 mg/kg APAP at both 6 and 24 h. However, some increased 
pallor remained, especially at 24 h (Fig.2-1A and not shown).  
 
Serum ALT, an indicator of liver injury, was 30-35 U/L after vehicle 
treatment at 6 h and 24 h, which was indistinguishable from untreated mice (Fig. 
2-1B and C). After 75 and 150 mg/kg APAP with and without NIM811 treatment, 
ALT remained unchanged. After 300 mg/kg APAP, ALT increased markedly to 
5,104 and 10,526 U/L at 6 and 24 h, respectively. When mice were pre-treated 
with NIM811, ALT after 300 mg/kg APAP decreased to 1,350 U/L and 2,947 U/L 
at 6 and 24 h, representing protection by more than 70% (Fig. 2-1B and C).  
 
High dose but not low dose APAP causes hepatic necrosis that is partially 
blocked by NIM811  
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After vehicle, liver histology after 6 and 24 h was normal and 
indistinguishable from untreated mice (Fig. 2-2 and not shown). After 300 mg/kg 
APAP, areas of pericentral necrosis developed at both 6 h and 24 h (Fig. 2-2, 
arrows). Hemorrhagic areas became prominent after 24 h (Fig. 2-2, asterisks). 
NIM811 pretreatment decreased hepatic necrosis after 300 mg/kg APAP from 
23.3% to 2.1% at 6 h and from 50.9% to 4.5% at 24 h (Fig. 2-2, lower right panel). 
By contrast after 75 and 150 mg/kg APAP with and without NIM811 pretreatment, 
liver architecture remained completely normal.  
 
High dose APAP causes mitochondrial depolarization and cell death in vivo 
at 6 hours  
At 6 h after vehicle, intravital multiphoton microscopy revealed punctate 
green Rh123 fluorescence in virtually all hepatocytes, indicating polarization of 
mitochondria (Fig. 2-3, far left). Cytosolic and nuclear areas had little green 
fluorescence. Red PI labeling of nuclei signifying cell death was absent. By 
contrast at 6 h after 300 mg/kg APAP, Rh123 fluorescence became diffuse and 
dim in pericentral hepatocytes (Fig. 2-3 far right, dashed line), indicating release 
of mitochondrial Rh123 due to depolarization of mitochondria . Additionally within 
areas with depolarized mitochondria, many nuclei became labeled with red-
fluorescing PI, which identified nonviable hepatocytes (Fig. 2-3 far right, arrows). 
Overlays of green and red images showed that in every instance PI-labeled 
hepatocytes contained depolarized mitochondria, as evidenced by dim, diffuse 
green Rh123 fluorescence. However, many other hepatocytes with dim, diffuse 
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Rh123 fluorescence had not yet labeled with PI. These results showed that at 6 h 
after high dose (300 mg/kg) APAP, mitochondrial depolarization occurred in 
pericentral hepatocytes and that this depolarization preceded onset of cell death.  
 
Low dose APAP causes reversible hepatocellular mitochondrial 
dysfunction in vivo at 6 hours  
At 6 h after 150 mg/kg APAP, many pericentral hepatocytes showed dim, 
diffuse Rh123 fluorescence, indicating mitochondrial depolarization (Fig. 2-3 
middle right, dashed line). Other hepatocytes had diffuse but relatively bright 
green Rh123 fluorescence, most likely indicating recent depolarization of 
mitochondria, since Rh123 fluorescence after release from mitochondria initially 
increases due to unquenching prior to eventual diffusion of Rh123 outside the 
cells (84). Despite consistent pericentral mitochondrial depolarization, PI labeling 
of nuclei was very rare, indicating the absence of cell death. These results show 
that at 6 h after 150 mg/kg APAP, mitochondrial depolarization occurred in 
pericentral areas without cell death. After 75 mg/kg APAP by contrast, 
mitochondria in virtually all hepatocytes remained polarized and were 
indistinguishable from the vehicle-treated group (Fig. 2-3 middle left).  
 
Progression of mitochondrial depolarization and cell death at 24 h after 
high dose APAP and recovery of mitochondrial dysfunction after low dose 
 Livers were also imaged by intravital multiphoton microscopy at 24 h after 
treatment with 75-300 mg/kg APAP. After high dose (300 mg/kg) APAP, loss of 
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Rh123 fluorescence indicating mitochondrial depolarization became more 
widespread than after 6 h, now involving pericentral and midzonal regions with 
periportal sparing (Fig. 2-4 far right, dashed line). PI-labeled nuclei also 
increased and were again confined within regions of mitochondrial depolarization 
(Fig. 2-4 far right, arrows).  
 
At 24 h after lower dose (150 mg/kg) APAP, Rh123 fluorescence was bright 
and punctate throughout the liver lobule, indicating that mitochondria of 
pericentral hepatocytes that were depolarized at 6 h had now repolarized at 24 h 
(Fig. 2-4 middle right). Additionally, PI labeling of nuclei was very rare. Overall, 
intravital images at 24 h after 150 mg/kg APAP were indistinguishable from 
vehicle treatment (Fig. 2-4 middle right). Similarly, intravital multiphoton images 
of livers at 24 h after 75 mg/kg APAP were indistinguishable from vehicle 
treatment (Fig. 2-4 middle left). 
 
Mitochondrial protein adducts, JNK activation and mitochondrial JNK 
translocation after APAP  
Formation of mitochondrial NAPQI protein adducts is an important initiating 
event for mitochondrial dysfunction (85). To assess if mitochondrial protein 
adducts correlated with cell necrosis, adducts were measured at 1 h, i.e., at the 
peak of adduct formation (80), after treatment with various doses of APAP. 
Mitochondrial NAPQI protein adducts were clearly detectable after the 150 and 
300 mg/kg dose but not after 75 mg/kg (Fig. 2-5A). Mitochondrial dysfunction and 
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oxidant stress induces JNK activation (11). To assess if mitochondrial protein 
adduct formation correlates with JNK activation, total JNK and pJNK levels were 
measured in the cytosol and in mitochondria (Fig. 2-5B).   After the high dose 
(300 mg/kg) of APAP, pJNK levels increased in hepatic cytosol and mitochondria 
after both 2 and 6 h (Fig. 2-5B). By contrast after 150 mg/kg APAP, pJNK 
increased in the cytosol and to a smaller extent in mitochondria only after 2 h. 
After 6 h total JNK remained unchanged in the cytosol, but pJNK had 
disappeared in both fractions (Fig. 2-5A). No JNK activation or mitochondrial 
translocation was observed after 75 mg/kg APAP (data not shown). Thus, 
mitochondrial protein adduct formation correlated with transient early JNK 
activation and pJNK translocation to mitochondria and with the transient 
mitochondrial depolarization at 6 h. However, sustained JNK activation and 
mitochondrial translocation, as observed after the 300 mg/kg dose, accompanied 
persistent mitochondrial depolarization and cell necrosis.   
 
Protection against mitochondrial depolarization by NIM811  
Because of previous reports that APAP induces the MPT, which in turn 
causes mitochondrial depolarization, we investigated whether the MPT inhibitor 
NIM811 would decrease hepatic mitochondrial depolarization in vivo after APAP 
treatment. After high dose (300 mg/kg) APAP with NIM811 pretreatment, 
substantially fewer pericentral hepatocytes displayed dim, diffuse Rh123 
fluorescence at both 6 and 24 h (Fig. 2-6 middle and far right, dashed line). PI 
labeling of nuclei also decreased (Fig. 2-6 far right, arrows). After low dose (150 
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mg/kg) APAP, NIM811 prevented mitochondrial depolarization virtually 
completely at 6 h, and all hepatocytes displayed bright punctate Rh123 
fluorescence, which was indistinguishable from NIM811 alone and vehicle alone 
(Fig. 2-6 middle and far left, compare to Fig. 2-3). 
 
Quantitation of mitochondrial depolarization and cell death  
Rh123 fluorescence and PI labeling were quantified for the various 
treatment groups. After vehicle, no depolarization of mitochondria occurred, as 
indicated by the absence of diffuse Rh123 fluorescence, and no cells were 
nonviable by nuclear PI labeling (Fig. 2-7). After 300 mg/kg APAP (high dose), 
58.3% of hepatocytes (area percent) displayed mitochondrial depolarization at 6 
h, which increased to 83.9% at 24 h. NIM811 pretreatment decreased 
depolarization to 16.4% and 27.3% at 6 and 24 h, respectively (Fig. 2-7A ). After 
300 mg/kg APAP, nuclear PI labeling increased from 0/high power field (HPF) 
after vehicle to 6.5/HPF at 6 h. Cell killing increased further to 8.8/HPF at 24 h. 
NIM811 pretreatment before 300 mg/kg APAP decreased nuclear PI labeling to 
0.07 and 0.5/HPF at 6 and 24 h (Fig. 2-7B). After low dose (150 mg/kg) APAP, 
NIM811 decreased depolarization areas from 15.7% to 0.4% at 6 h. 
Depolarization was absent at 24 h after low dose APAP administration with and 
without NIM811 pretreatment. Cell killing (PI labeling) was absent at both 6 and 
24 h after low dose APAP administration with and without NIM811 pretreatment. 
 
Low dose APAP causes reversible hepatic steatosis  
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When mitochondrial depolarization occurred after APAP, round dark voids 
frequently developed in hepatocytes within the diffuse cytoplasmic fluorescence 
of Rh123 (Fig. 2-3, bottom middle right inset, arrows). To determine whether 
these dark voids represented fat droplets, we stained frozen sections with Oil-
Red-O. After vehicle treatment, Oil-Red-O-stained fat droplets were small and 
sparse (Fig. 2-8 left). At 6 h after lower dose (150 mg/kg) APAP, numerous Oil-
Red-O-stained fat droplets became evident in pericentrial hepatocytes (Fig. 2-8 
middle), but by 24 h the livers had recovered from this steatosis, and fat droplets 
were again small and sparse (Fig. 2-8 right). Thus, lower dose (150 mg/kg) 
APAP caused both pericentral mitochondrial depolarization and steatosis, which 
was transient and not accompanied by cell death, necrosis or ALT release. 
 
Hepatic steatosis caused by low dose APAP is associated with 
mitochondrial depolarization  
To assess the relationship of steatosis with mitochondrial depolarization 
after low dose (150 mg/kg) APAP, mice were infused simultaneously with ΔΨ-
indicating TMRM and lipid droplet-indicating BODIPY. After vehicle, virtually all 
hepatocytes displayed punctate, red fluorescence of TMRM, indicating 
mitochondrial polarization (Fig. 2-9A top left). Fat droplets labeled by green-
fluorescing BODIPY were small and relatively sparse. At 6 h after low dose (150 
mg/kg) APAP, TMRM fluorescence in pericentral hepatocytes became diffuse 
with development of round dark voids, as observed with Rh123 labeling (Fig. 2-
9A bottom right, compare to Fig. 2-3). BODIPY revealed that these dark voids 
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coincided with fat droplets inside hepatocytes with depolarized mitochondria (Fig. 
2-9A top and bottom middle). NIM811 decreased both mitochondrial 
depolarization and steatosis at 6 h (Fig. 2-9A top right). At 24 h after 150 mg/kg 
APAP, mitochondria repolarized (as observed with Rh123), and the number of 
BODIPY stained green fat droplets decreased (Fig. 2-9A bottom right). The 
percent of BODIPY stained area was quantified after various treatments. After 
vehicle, 2.1% of area was labeled with BODIPY, which increased to 6.4% at 6 h 
after 150 mg/kg APAP and then decreased to 1.7% at 24 h. NIM811 





In vivo in mice, hepatic NAPQI-protein adduct formation peaks at 0.5-1 h 
after APAP treatment (23) followed by mitochondrial dysfunction and cell death. 
Liver damage assessed by ALT release begins within 3 h after APAP and 
increases progressively to peak after about 12-24 h (86). If APAP toxicity is not 
fatal, ALT typically returns to normal within 4 days (87). Our data confirm this 
time-dependent hepatotoxicity. After 300 mg/kg APAP, ALT increased, and 
macroscopic changes of liver appearance (mottling, pallor) and outright necrosis 
developed at 6 h, which became more severe by 24 h (Fig. 2-1 and 2-2). By 
contrast, 75 and 150 mg/kg APAP did not induce macroscopic liver changes, 
increase ALT or cause pericentral necrosis in agreement with previous reports 
(88). Thus, 75 mg/kg and 150 mg/kg doses of APAP were not toxic by 
conventional indices of hepatic injury damage, whereas 300 mg/kg dose was 
unequivocally hepatotoxic.  
 
Previous studies in cultured mouse hepatocytes show that toxic doses of 
APAP induce mitochondrial depolarization and inner membrane permeabilization 
(16, 31, 41). To visualize changes of hepatic mitochondrial function in vivo after 
APAP, we used intravital multiphoton microscopy. Our studies revealed that 
mitochondrial depolarization and cell death developed in pericentral hepatocytes 
within 6 h after 300 mg/kg APAP and became more severe after 24 h (Fig. 2-3, 2-
4 and 2-7), indicating that this toxic dose of APAP caused sustained and 
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irreversible mitochondrial dysfunction in vivo. Unexpectedly, mitochondrial 
depolarization in pericentral hepatocytes also occurred in mice at 6 h after 
treatment with 150 mg/kg, which was a “nontoxic” dose of APAP not causing 
necrosis or enzyme release. Despite this mitochondrial depolarization, nuclear PI 
labeling after 150 mg/kg APAP was not observed at any time point examined. 
Indeed, mitochondrial depolarization observed after 6 h spontaneously reversed 
after 24 h (Fig. 2-3 and 2-7). Mitochondrial images at different distances from the 
liver surface confirmed these findings (Fig. 2-10). Thus, 150 mg/kg APAP caused 
transient mitochondrial dysfunction that reversed spontaneously and did not 
induce cell death. 
 
Mitochondrial NAPQI protein adduct formation is thought to trigger an initial 
oxidant stress, which can induce JNK activation (89). Activated pJNK 
translocates to mitochondria during APAP hepatotoxicity, an event that appears 
to enhance ROS generation and precipitate the MPT and cell death (89). Our 
data confirmed that early JNK activation and mitochondrial pJNK translocation 
occurs only after a dose of APAP that triggered relevant mitochondrial protein 
adduct formation. This early JNK activation also correlated with the mitochondrial 
depolarization after these doses. However, at the lower, nontoxic dose, JNK 
activation, mitochondrial pJNK translocation and mitochondrial depolarization 
were transient, reversible events. Sustained JNK activation and sustained 
presence of pJNK in the mitochondria appears to be necessary for permanent 
mitochondrial depolarization and development of cell necrosis. This is consistent 
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with the hypothesis that prolonged JNK activation is needed to amplify the 
mitochondrial oxidant stress that triggers the MPT and causes cell necrosis (89). 
The main difference between the nontoxic 150 mg/kg dose and the toxic 300 
mg/kg dose is not the initial depletion of hepatic glutathione but the recovery of 
these glutathione levels, which is substantially accelerated after the lower dose 
(23). A faster recovery of hepatic glutathione by giving glutathione or its 
precursor, N-acetylcysteine, during the most critical phase of mitochondrial 
oxidant stress and peroxynitrite formation was shown to dramatically protect 
against APAP-induced cell death (90). These findings stress the importance of 
prolonged JNK activation for permanent mitochondrial depolarization and 
emphasize possible therapeutic targets to block this process.  
 
No mitochondrial depolarization was observed after administration of 75 
mg/kg APAP (Fig.2-3), which might be considered the real maximal safe dose of 
APAP for mice. Nonetheless, GSH can become maximally depleted within 1 h 
leading to NAPQI protein adduct formation within 2 h even at APAP doses below 
those causing hepatic necrosis (31). Thus after treatment with 75 mg/kg APAP, 
we cannot not exclude the possibility that mitochondrial dysfunction happened at 
an earlier time and had already recovered by 6 h when we first performed our 
intravital multiphoton experiments. The dose of 75 mg/kg corresponds 
approximately to the accepted 4 g daily limit for APAP use by humans, which 
supports current clinical recommendations (8). However, mice metabolize APAP 
more rapidly than humans (91). Thus, doses in humans less than 4 g might still 
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cause transient mitochondrial dysfunction that synergizes with other 
hepatocellular stresses to cause hepatic necrosis and enzyme release. 
 
Previous studies implicate the MPT in the mechanism of APAP-induced 
hepatotoxicity (16, 30, 31). The MPT inhibitor CsA delays APAP-induced cell 
killing in cultured mouse hepatocytes and decreases hepatic injury in APAP-
treated mice (16, 30, 41). NIM811, a nonimmunosuppressive CsA analog, blocks 
the MPT similarly to CsA and protects in vivo in several experimental models of 
hepatic injury, including cold storage/reperfusion injury, small-for-size liver 
transplantation, CCl4-induced liver fibrosis, hepatectomy and cholestasis (25, 27, 
29, 92). Here using intravital multiphoton microscopy, we showed that NIM811 
substantially decreased mitochondrial depolarization and cell death at both 6 h 
and 24 h after treatment of mice with 300 mg/kg APAP (Fig. 2-6 and 2-7), results 
that confirm and extend the conclusion that the MPT is a principal mechanism 
contributing to APAP-induced liver injury. NIM811 also blocked transient 
mitochondrial depolarization at 6 h after 150 mg/kg APAP (Fig. 2-6 and 2-7). 
Thus, reversible mitochondrial injury after low dose APAP was still related to PT 
pore activity. Similar reversible CsA-sensitive mitochondrial depolarization occurs 
in somatosensory cortex in an in vivo mouse stroke model (93). Moreover in 
isolated mitochondria, PT pore opening is well established to be reversible (94). 
Thus, reversible PT pore opening likely explains the transient nature of 





PT pores have two open conductance modes - a Ca2+-activated and CsA-
sensitive regulated mode associated with early PT pore opening and an 
unregulated mode occurring later, which does not require Ca2+ and is not 
inhibited by CsA (24). In cultured mouse hepatocytes, CsA and NIM811 delayed 
but did not prevent APAP-induced mitochondrial depolarization, indicating APAP 
initially induces a regulated MPT that is later superseded by an unregulated MPT 
(16). Here we found that cytoprotection by NIM811 persisted after 24 h of APAP 
administration (Fig. 5). This is consistent with previous in vivo data showing 
protection in cyclophilin D-deficient mice after a dose of 200 mg/kg APAP (95). 
However, this protective effect disappeared when a dose of 600 mg/kg APAP 
was used (96). Thus, both in vitro and in vivo the MPT can be regulated after a 
moderate stress but is unregulated after a more severe stress. Our results 
suggest that NIM811 might have clinical value to prevent and even treat APAP-
induced mitochondrial dysfunction and hepatotoxicity under certain conditions.  
 
At 6 h after a lower “nontoxic” dose of APAP, round dark voids appeared in 
the cytoplasm of hepatocytes with depolarized mitochondria. Intravital 
multiphoton imaging of BODIPY identified these voids as lipid droplets, which oil 
red O staining of frozen sections confirmed (Fig 2-8, 2-9). However, lipid droplets 
disappeared at 24 h when mitochondria repolarized (Fig 2-9A). These findings 
are in agreement with reports that APAP induces hepatic steatosis in some 
individuals (97). A proposed mechanism for this steatosis is inhibition by NAPQI 
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and oxidative stress of fatty acid oxidation enzymes located in the mitochondria 
matrix (98). Indeed, acute mitochondrial dysfunction for a variety of reasons is 
well established to cause hepatic steatosis (99, 100). Protection by NIM811 
against steatosis implies that PT pore opening is the cause of mitochondrial 
dysfunction after APAP and the consequent steatotic transformation of 
hepatocytes (Fig. 2-9B).  
 
Mitochondrial depolarization is a strong signal inducing mitochondrial 
autophagy, or mitophagy (101, 102). Thus, MPT-dependent mitochondrial 
depolarization may underlie increased mitophagy after APAP, as recently 
reported (103). Similarly, reversible mitochondrial depolarization leading to 
steatosis occurs after acute ethanol treatment of mice, which may also stimulate 
enhanced hepatic mitophagy (83, 104). Thus, mitochondrial depolarization may 
be a common event leading both to steatosis and mitophagy. However, once 
cells lose viability, hepatocytes release their fat droplets, such that steatosis is 
never present in necrotic regions of the liver. 
 
In conclusion, the present study shows that even “nontoxic” doses of APAP 
that do not cause transaminase release and histological necrosis can 
nonetheless lead to transient hepatocellular mitochondrial dysfunction and 
steatosis. Unlike overdose-induced hepatotoxicity, the effects of subtoxic APAP 
are comparably mild and reversible, correlating with transient JNK activation and 
mitochondrial translocation. However in patients subjected to other stresses such 
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as extensive malnourishment, APAP-induced transient mitochondrial dysfunction 
may become magnified and lead to overt hepatic damage. Serial ingestion of 
APAP may compound this danger, since there may be inadequate time for 
hepatocytes to recover between dosings. Protection against mitochondrial 
dysfunction by the MPT inhibitor NIM811 implies that MPT onset plays an 
important role in mitochondrial dysfunction after both low and high dose APAP. 
These new findings suggest that even lower “nontoxic” doses can trigger a 







Figure 2-1.  Low dose APAP does not cause gross liver changes and ALT 
release. Mice were administered vehicle or APAP at low (75, 150 mg/kg) and 
high (300 mg/kg) doses. NIM811 (10 mg/kg) or vehicle was gavaged 1 h before 
APAP. In (A), photographs of livers were taken before tissue harvest at 6 h and 
24 h after vehicle or APAP injection. Bar is 3 mm. In (B) and (C), serum ALT was 
measured at 6 h and 24 h, respectively. *, p<0.05 versus vehicle; †, p<0.05 








Figure 2-2. High dose but not low dose APAP causes liver necrosis. 
Mice were treated with vehicle, NIM811 and/or APAP, as described in Fig. 2-1, 
and necrosis was assessed by H&E histology. Black arrows identify necrotic 
areas. Asterisks (*) identify hemorrhage. Bar is 250 µm. Area percent of necrosis 
was quantified in liver sections by image analysis of 10 random fields per liver 
(lower right panel). Necrosis in vehicle and 75 mg/kg APAP groups was absent 








Figure 2-3. After 6 h, lower dose APAP causes mitochondrial depolarization 
without cell death, whereas high dose APAP causes sustained 
mitochondrial dysfunction accompanied by cell death. Mice were treated 
with vehicle or APAP, as described in Fig. 2-1. Intravital multiphoton microscopy 
was performed after infusion of Rh123 and PI, as described in MATERIALS AND 
METHODS. Shown are representative overlay images of green Rh123 and red 
PI fluorescence collected from livers at 6 h after vehicle (far left), 75 mg/kg 
APAP (middle left), 150 mg/kg APAP (middle right) or 300 mg/kg APAP (far 
right) . Top and bottom rows show low and high power images, respectively. 
Punctate labeling with Rh123 signifies mitochondrial polarization, whereas dim 
diffuse Rh123 staining denotes mitochondrial depolarization (white dashed line). 
Nuclear PI labeling signifies cell death (white arrows). A higher magnification 
inset in (middle right) showed illustrates dark voids in the diffuse Rh123 








Figure 2-4. Mitochondrial function recovers at 24 h after lower dose APAP, 
whereas mitochondrial dysfunction is sustained and accompanied by cell 
death after high dose APAP. Mice were treated with vehicle or APAP, as 
described in Fig. 2-1, and multiphoton microscopy was performed, as described 
in Fig. 3. Shown are representative overlay images of green Rh123 and red PI 
fluorescence collected from livers at 24 h after vehicle (far left), 75 mg/kg APAP 
(middle left), 150 mg/kg APAP (middle right) or 300 mg/kg APAP (far right). 
White dashed lines outline areas of mitochondrial depolarization, and white 







Figure 2-5. APAP-induced mitochondrial protein adducts and JNK 
activation. Mice were treated with APAP, as described in Fig. 2-1, and 
mitochondrial protein adducts were measured by HPLC with electrochemical 
detection 1 h after APAP (A); pJNK and total JNK in hepatic cytosolic and 
mitochondrial fractions were determined by Western analysis after 2 and 6 h. 
PBS, saline (B). 
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Figure 2-6. NIM811 decreases hepatocellular cell death and/or 
mitochondrial depolarization after both low and high dose APAP. Mice were 
treated with vehicle, NIM811 and APAP, as described in Fig. 2-1, and 
multiphoton microscopy was performed. As indicated, shown are representative 
overlay images of green Rh123 and red PI fluorescence collected from NIM811-
pretreated livers at 6 h and 24 h after vehicle and different doses of APAP. 
Punctate labeling of Rh123 signifies mitochondrial polarization, whereas diffuse 
cellular staining denotes mitochondrial depolarization (dashed line). Nuclear PI 
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Figure 2-7. Protection by NIM811 against depolarization and cell death 
induced by APAP. Mice were treated with vehicle, NIM811 and/or APAP, as 
described in Fig. 2-3 and 2-6. Percent area of mitochondrial depolarization is 
plotted for various treatment groups for 3-4 livers per group (A). Numbers per 









Figure 2-8. Low dose APAP induces transient hepatic steatosis. Mice were 
administered vehicle or 150mg/kg APAP. Steatosis was assessed by oil red O 
staining after vehicle and at, 6 h and 24 h after APAP. Top and bottom rows are 






Figure 2-9. NIM811 prevents steatosis induced by low dose APAP. (A) Mice 
were treated with vehicle, NIM811 and APAP, as described in Fig. 1. TMRM and 
BODIPY were infused, and intravital multiphoton microscopy was performed. 
Shown are representative images of green BODIPY and red TMRM fluorescence 
collected from livers after vehicle, 6 h after APAP, 6 h after APAP plus NIM811, 
and 24 h after APAP. Bottom left and middle are the separate red and green 
channels of the area shown by the inset in the top middle. Note that green 
BODIPY labeling of fat droplets coincided with round dark cytoplasmic voids in 
the TMRM fluorescence. In (B), area percent of BODIPY staining was quantified. 







Figure 2-10. Mitochondrial depolarization increases at greater depth into the 
liver after low dose APAP. Mice were treated with vehicle or 150 mg/kg APAP, as 
described in Fig. 2-1, and multiphoton microscopy was performed. Shown are 
representative overlay images of green Rh123 and red PI fluorescence collected 
at 25 µm, 55 µm, 85 µm and 115 µm from the liver surface at 6 h after vehicle 
(top), 6 h after APAP (middle) and 24 h after APAP (bottom). Dashed lines 










Translocation of Iron from Lysosomes to Mitochondria 
during Acetaminophen-Induced Hepatocellular Injury, 





Acetaminophen (APAP) overdose causes hepatotoxicity involving 
mitochondrial dysfunction and the mitochondrial permeability transition (MPT). 
Reactive oxygen species (ROS) play an important role in APAP-induced 
hepatotoxicity. Iron is a critical catalyst for ROS formation. Previous studies show 
that disrupted lysosomes release ferrous iron (Fe2+) into the cytosol during APAP 
hepatotoxicity, which triggers the MPT and cell killing. Here, our aim was to 
investigate whether iron released from lysosomes after APAP is then taken up 
into mitochondria via the mitochondrial electrogenic Ca2+, Fe2+ uniporter (MCFU) 
to cause MPT onset, mitochondrial depolarization and cell death, which is 
prevented by the lysosomally targeted iron chelator, starch-desferal, and the 
MCFU inhibitor, minocycline. Hepatocytes were isolated from fasted male 
C57BL/6 mice. Necrotic cell killing was assessed by propidium iodide fluorimetry. 
Mitochondrial membrane potential was visualized by confocal microscopy of 
rhodamine 123 (Rh123) or tetramethylrhodamine methylester (TMRM). 
Chelatable Fe2+ was monitored by quenching of calcein (cytosol) and 
mitoferrofluor (MFF, mitochondria). ROS generation was monitored by confocal 
microscopy of MitoSox Red and plate reader fluorimetry of 
chloromethyldihydrodichlorofluorescein diacetate (cmH2DCF-DA). The iron 
chelator, starch-desferal (1 mM), and the MCFU inhibitors, Ru360 (100 nM) and 
minocycline (4 µM), 1 h before APAP (10 mM) decreased cell killing from 83% to 
41%, 57% and 53% at 10 h after APAP, respectively. Progressive quenching of 
calcein and MFF began after ~4 h, signifying increased cytosolic and 
52 
 
mitochondrial chelatable Fe2+. Mitochondria then depolarized after ~10 h. 
Dipyridyl, a membrane-permeable iron chelator, dequenched calcein and MFF 
fluorescence after APAP. Starch-desferal, but not Ru360 and minocycline, 
suppressed cytosolic calcein quenching, whereas s-desferal, Ru360 and 
minocycline all suppressed mitochondrial MFF quenching and mitochondrial 
depolarization. S-desferal, Ru360 and minocycline also each decreased ROS 
formation. Moreover, minocycline 1 h after APAP decreased cell killing by half. In 
conclusion, release of chelatable Fe2+ from lysosomes followed by uptake into 
mitochondria via MCFU occurs during APAP hepatotoxicity. Increased 
mitochondrial iron then catalyzes ROS formation, which triggers the MPT and cell 
killing. The efficacy of minocycline post-treatment shows minocycline as a 






Acetaminophen (APAP) overdose produces severe hepatotoxicity and is 
the leading cause of acute liver failure in North America. Although extensively 
studied, the mechanism of APAP-induced liver injury is incompletely understood. 
It is widely accepted that APAP toxicity is initiated by cytochrome P450–mediated 
metabolism of APAP to produce the reactive metabolite, N-acetyl-p-
benzoquinoneimine (NAPQI), which is in turn detoxified by adduction to cellular 
glutathione (GSH) (5, 6). However, as GSH becomes exhausted, NAPQI begins 
to bind covalently to cellular proteins and promote oxidative stress with onset of 
the mitochondrial permeability transition (MPT), resulting in hepatocellular death 
(16, 17, 39). Oxidative stress is an important mediator of toxicity and has been 
suggested as a major mechanism in APAP-induced hepatotoxicity. Formation of 
reactive oxygen species (ROS) increases after APAP exposure, and agents that 
augment antioxidant defenses and scavenge ROS protect against APAP toxicity 
in vitro and in vivo (38).  
 
Iron is a catalyst for OH• formation, a particularly toxic ROS. Iron has been 
identified to have a critical role in oxidative stress in many injuries, including 
hepatic injury, myocardial injury and neurological injury (66-68). Iron also 
appears to play an important role in APAP hepatotoxicity but does not promote 
formation of NAPQI protein adducts (71, 105). In liver and other tissues, two 
pools of iron exist. The first is “non-chelatable” iron that is sequestered in ferritin 
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and as structural components of proteins (e.g., heme, iron–sulfur complexes 
[ISC]). Non-chelatable iron cannot be removed by conventional iron chelators 
such as desferal. The second pool is “chelatable” iron, which includes free iron 
and iron loosely bound a wide variety of anionic intracellular molecules. Previous 
studies identified the lysosomal/endosomal compartment as a source of 
mobilizable chelatable iron (41, 53, 106). Disruption of lysosomes occurs after 
APAP, which is prevented by the iron chelator, desferal. Desferal also prevents 
mitochondrial depolarization and protects hepatocytes against cell death after 
APAP (41).  
 
The mitochondrial Ca2+ and Fe2+ uniporter (MCFU) transports Fe2+ into 
mitochondria during oxidative injury to hepatocytes (53, 61). Ru360 and 
minocycline inhibit MCFU and protect cells from chemical hypoxia and I/R injury 
(107, 108). Since Ru360 and minocycline block Fe2+ uptake via MCFU, 
protection might be by preventing mitochondrial Fe2+ uptake (108, 109).  
 
Accordingly, I hypothesized that iron released from lysosomes is taken up 
into mitochondria via the mitochondrial MCFU to promote iron-dependent 
formation of OH•, mitochondrial depolarization and cell death in APAP-induced 
toxicity. Therefore, my goals were characterize pathways of this iron movement 
and whether blockade of iron mobilization protects against APAP toxicity to 
mouse hepatocytes. The data indicate a key role of MCFU in iron mobilization 
into mitochondria and the prevention of ROS production and APAP hepatotoxicity 
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Materials and Methods 
Materials 
 
Calcein-AM, calcein-free acid, TMRM, MitoSox Red and cmH2DCF-DA 
were purchased from Life Technologies (Grand Island, NY). Starch-desferal was 
the generous gift of Biomedical Frontiers (Minneapolis, MN). Minocycline, 
rhodamine 123 (Rh123), propidium iodide (PI), and other reagents were 
purchased from Sigma-Aldrich (St. Louis, MO). 
 
Isolation and Culture of Mouse Hepatocytes 
All experiments were conducted using animal protocols approved by the 
Institutional Animal Care and Use Committee. Hepatocytes were isolated from 20 
to 25 g overnight-fasted male C57BL/6 mice (Jackson Laboratory, Bar Harbor, 
ME) via collagenase perfusion through the inferior vena cava, as described 
previously (53). Hepatocytes were resuspended in Waymouth’s medium MB-
752/1 supplemented with 2 mM L-glutamine, 10% fetal calf serum, 100 nM 
insulin, 100 nM dexamethasone, 100 U/ml penicillin, and 100 µg/ml streptomycin, 
as previously described (110). Cell viability was greater than 85% by trypan blue 
exclusion. Hepatocytes were plated on 0.1% type 1 rat-tail collagen-coated 24-
well microtiter plates (1.5 × 105 cells per well) or on glass bottom Petri dishes 
(3.0 × 105 cells per dish, Maktek Corporation, Ashland, MA). After attaching for 3 
h in humidified 5% CO2, 95% air at 37
0C, hepatocytes were washed once and 
placed in hormonally defined medium (HDM) consisting of RPMI 1640 (Gibco, 
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Rockville, MD) supplemented with 240 nM insulin, 2 mM L-glutamine, 1 µg/ml 
transferrin, 0.3 nM selenium, 100 U/ml penicillin, and 100 µg/ml streptomycin at 
pH 7.4.  
 
Fluorimetric Assay of Cell Viability and Reactive Oxygen Species  
Cell death and ROS production were assessed using a NovoStar multiwell 
plate reader (BMG Lab Technologies, Offenburg, Germany), as previously 
described (48, 49). Briefly, after attachment to 24-well plates for 3 h, hepatocytes 
were washed once and replaced with HDM containing 30 µM propidium iodide 
(PI, Invitrogen, Eugene, OR) or 10 µM chloromethyldihydrodichlorofluorescein 
diacetate (cmH2DCF-DA, Invitrogen). In some experiments, hepatocytes were 
preincubated 1 h with 1 mM starch-desferal (Biomedical Frontiers, Minneapolis, 
MN), 100 nM Ru360 (Calbiochem, San Diego, CA) or 4 µM minocycline (Sigma-
Aldrich, St. Louis, MO). After pretreatment, hepatocytes were then incubated with 
10 mM APAP.  
 
PI fluorescence from each well was measured at excitation and emission 
wavelengths of 544 nm and 620 nm (40-nm bandpass), respectively. For each 
well, fluorescence was first measured at 20 min after addition of PI (Initial) and 
then at various times after treatment with APAP (X). Experiments were 
terminated by permeabilizing plasma membranes with 375 μM digitonin. After 
another 20 min, a final fluorescence measurement (Final) was collected. The 
percentage of nonviable cells (D) was calculated as D = 100(X -Initial)/(Final - 
58 
 
Initial). Cell killing assessed by PI fluorimetry correlates closely with trypan blue 
exclusion and enzyme release as indicators of oncotic necrosis (124, 126). 
 
Green fluorescence of cmDCF from each well was measured at excitation 
and emission wavelengths of 485 nm and 520 nm, respectively. Conversion of 
nonfluorescent cmH2DCF-DA to green fluorescing cmDCF indicates generation 
of hydroperoxides after lipid peroxidation. 
 
Loading of fluorophores  
Hepatocytes plated on cover glasses were incubated in HDM with 50 mM 
HEPES (pH 7.4) to maintain pH. In some experiments to stabilize the plasma 
membrane after APAP-induced disruption of mitochondrial metabolism, 
hepatocytes were incubated with 20 mM fructose plus 5 mM glycine (16). After 
1.5 h of treatment with 10 mM APAP or no addition, cells were loaded with 500 
nM rhodamine 123 (Rh123) and 1 µM mitoferrofluor (MFF) for 20 min. Cells were 
then washed once and incubated in HDM at pH 7.4 containing 100 nM Rh123, 
but no MFF. In some experiments, hepatocytes were loaded with 300 nM 
tetramethylrhodamine methylester (TMRM) and 1 µM calcein acetoxymethyl 
(calcein-AM) for 20 min. Cells were then washed once and incubated in HDM at 
pH 7.4 containing 100 nM TMRM, 300 µM calcein free acid and 3 µM PI. For 
assessing ROS formation in some experiments, hepatocytes were loaded with 1 
µM MitoSox Red for 15 min.  Cells were then washed three times and incubated 
in HDM at pH 7.4.  
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Laser Scanning Confocal Microscopy 
Hepatocytes loaded with the various combinations of fluorophores were 
placed in environmental chambers at 37 ̊C on the stage of an Olympus FV10i 
laser scanning confocal microscope (Center Valley, PA). Green fluorescence 
(Rh123, calcein) was excited at 473 nm, and emission was collected through a 
490-540-nm band-pass filter. Red fluorescence (TMRM, PI, MFF) was excited at 
559 nm, and emission was imaged through a 570-670-nm band-pass filter. 
MitoSox Red fluorescence was excited at 473 nm, and emission was collected 
through a 570-670-nm band-pass filter.  
 
Image Analysis 
Calcein, Rh123, MFF and MitoSox Red fluorescence was quantified using 
Adobe Photoshop CS4 (San Jose, CA, USA). Briefly, cells were outlined, and 
mean fluorescence intensity was determined by histogram analysis of the 
appropriate red and green channels (111). Background values were obtained 
from images collected while focusing within the coverslip and were subtracted 
from mean fluorescence of each field. 
 
Statistics 
Data are presented as means ± SEM. Images shown are representative of 
three or more experiments. Means were compared by Student t test using P ≤ 
0.05 as the criterion of significance. Experiments were representative of at least 





Iron chelation and MCFU inhibitors decrease APAP-induced necrotic cell 
killing 
APAP-induced cell killing was determined by PI fluorescence assay. When 
mouse hepatocytes were exposed to 10 mM APAP (toxic dose for mouse 
hepatocytes), loss of cell viability increased to 40% after 6 hours and to 83% 
after 10 hours (Fig. 3-1), as observed previously (16). After individual treatment 
with 1 mM starch-desferal, 100 nM Ru360 and 4 µM minocycline 1 h before 
APAP addition, cell killing after APAP decreased substantially at 6 to 10 h (Fig. 3-
1). Because starch-desferal is a lysosomally targeted iron chelator, and Ru360 
and minocycline are MCFU inhibitors, these results implicated important roles for 
lysosomal iron and MCFU in APAP hepatotoxicity. 
  
APAP increases cytosolic and mitochondrial chelatable iron 
To visualize iron mobilization into the cytosol of hepatocytes during APAP 
hepatotoxicity, hepatocytes were co-loaded with TMRM, calcein-AM and PI. 
TMRM is a cell-permeant, cationic, red-fluorescing dye that is sequestered by 
active mitochondria as an indicator of mitochondrial polarization. Calcein-AM 
localizes in cytosol and is quenched by chelatable Fe2+. To prevent necrotic cell 




When hepatocytes were exposed to 10 mM APAP, green cytosolic calcein 
fluorescence began to decrease at 4 h and progressively decreased to intensities 
well below that of calcein free acid (300 µM) placed in the extracellular medium, 
as observed previously (41). Calcein quenching was nearly complete at 10 h 
(Fig. 3-2). Mitochondria began to lose red TMRM fluorescence at 4 h, indicating 
mitochondrial depolarization and were completely depolarized at ~10 h. The 
membrane-permeant iron chelator, DPD, partially restored intracellular calcein 
fluorescence (Fig. 3-2). Subsequent plasma membrane permeabilization with 
digitonin led to nuclear labeling with PI, indicating cell death. These data are 
consistent with the conclusion that an increase of cytosolic Fe2+ occurs after 
APAP treatment. 
 
To assess mobilization of chelatable iron into mitochondria after APAP, 
hepatocytes were co-loaded with Rh123 and MFF. PI was added after DPD to 
avoid any possible interference of PI fluorescence with MFF fluorescence. Rh123 
like TMRM is an indicator of mitochondrial polarization but fluoresces green. MFF 
is a Fe2+-quenched cationic red fluorophore that accumulates electrophoretically 
and binds covalently inside mitochondria. During control incubations, Rh123 and 
MFF fluorescence was relatively unchanged after an incubation of up to 12 h 
(Fig. 3-3A and not shown). At 2 h after APAP, mitochondrial MFF fluorescence 
was bright and comparable with control hepatocytes (Fig. 3-3B). Subsequently, 
mitochondrial MFF fluorescence progressively became quenched, beginning at 4 
h and becoming complete within 10 h (Fig. 3-3B). Mitochondrial depolarization 
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(loss of Rh123) also began to occur at 4 h and was complete at ~10 h. DPD 
again partially restored quenched MFF fluorescence, and digitonin led to nuclear 
PI staining (Fig 3-3B). Together with Fig. 3-2, these results indicate that APAP 
leads to iron release into the cytosol and that some of this iron enters 
mitochondria. 
 
Starch-desferal, but not Ru360 and minocycline, suppresses cytosolic 
calcein quenching 
Previous studies indicated that lysosomes release iron after oxidative stress 
in hepatocytes (41, 53). To investigate further the origin of cytosolic iron after 
APAP, mouse hepatocytes were preincubated with the lysosomally targeted iron 
chelator, starch-desferal (1 mM). Starch-desferal inhibited APAP-induced 
mitochondrial depolarization and cytosolic calcein quenching (Fig. 3-4). 
Quantification revealed that calcein fluorescence decreased only 28% at 10 h in 
starch-desferal group, compared to 73% in APAP group (Fig. 3-6). Cytosolic 
calcein quenching was not prevented by the MCFU inhibitors, Ru360 and 
minocycline (Fig. 3-5). Starch-desferal is membrane impermeant and is taken up 
into the lysosomal/endosomal compartment via endocytosis to chelate iron but 
not other cations that quench calcein (112, 113). Thus, prevention of quenching 
of cytosolic calcein fluorescence by starch-desferal indicated that chelatable iron 




Starch-desferal, Ru360 and minocycline prevent mitochondrial MFF 
quenching and mitochondrial depolarization 
To further assess the role of MCFU in translocation of chelatable iron into 
mitochondria during APAP hepatotoxicity, mouse hepatocytes were pretreated 
with the MCFU inhibitors, Ru360 (100 nM) and minocycline (4 µM), 1 h before 
APAP. Ru360 and minocycline largely suppressed the quenching of MFF in 
mitochondria after APAP that otherwise began about 4 h after APAP (Fig. 3-7, 
compare to Fig. 3-3). Starch-desferal also protected against MFF quenching after 
APAP (Fig. 3-8). Fluorescence quantification revealed that MFF fluorescence 
after APAP decreased 20% and 30% at 10 h, respectively, in the Ru360- and 
minocycline-treated groups, compared to 68% in the APAP only group (Fig. 3-9). 
Protection by starch-desferal against MFF quenching was slightly stronger than 
that by Ru360 and minocycline, although only the difference between starch-
desferal and minocycline was statistically significant (p<0.01) (Fig. 3-9). Starch-
desferal, Ru360 and minocycline each nearly fully protected against loss of 
Rh123 fluorescence after APAP (Fig. 3-9).These data indicated that MCFU was 
responsible for iron uptake into mitochondria after APAP, which then induced 
mitochondrial depolarization. 
 
APAP induces ROS formation that is suppressed by starch-desferal, Ru360 
and minocycline 
Previous studies show that APAP leads to ROS formation (38, 114). To 
determine the role of chelatable iron in ROS formation after APAP, mouse 
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hepatocytes were pretreated with starch-desferal, Ru360 and minocycline 1 h 
before APAP and then loaded with mitochondrial superoxide indicator, MitoSox 
Red, or the general oxidative stress indicator, cmH2DCF-DA. 
 
Confocal microscopy revealed that mitochondrial MitoSox Red fluorescence 
increased 116% of its value at 6 h compared to 4 h after APAP, indicating ROS 
generation in mitochondria (Fig. 3-10, 3-11). At later time points, MitoSox Red 
fluorescence increased by 163%, although the signal appeared to be 
approaching saturation. With starch-desferal, Ru360 and minocycline 
pretreatment, MitoSox Red fluorescence increased much more slowly after 
APAP (Fig. 3-10, 3-11).  
 
Plate reader fluorimetry also showed a progressive increase of cmDCF 
fluorescence after APAP, confirming ROS generation in a larger cell population 
(Fig. 3-12). Between 2 and 4 h after APAP, cmDCF fluorescence increased only 
slightly. By contrast, between 6 and 10 h after APAP, cmDCF fluorescence 
increased by 886% over its value at 2 h. Starch-desferal, Ru360 and minocycline 
inhibited this ROS generation by about half at all time points (Fig. 3-12). Together 
with Figs 3-3, 3-7, 3-8 and 3-10, these results indicate that iron uptake by 
mitochondria catalyzed ROS formation, which triggered MPT onset and 
subsequent cell death in APAP hepatotoxicity. 
 
Minocycline treatment after APAP decreases cell killing 
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To test the therapeutic effect of minocycline against APAP hepatotoxicity, 
mouse hepatocytes were post-treated 1 h after APAP with minocycline, and cell 
killing was determined by PI fluorimetry. After APAP, hepatocytes progressively 
lost viability, leading to 73% and 83% cell death at 8 h and 10 h, respectively, 
which minocycline attenuated to 31% and 50% at 8 h and 10 h, respectively (Fig. 
3-13). These results extended the benefit of minocycline against APAP 






In agreement with our previous findings that produces time-dependent 
necrotic cell killing (16), 10 mM APAP caused 40% and 83% cell killing at 6 h and 
10 h, respectively (Fig 3-1). A role of iron in APAP hepatotoxicity has been 
implied from the observation that the iron chelator, desferal, protects hepatocytes 
after APAP (41, 71). Likewise as shown previously, starch-desferal also 
decreased cell killing by half (Fig 3-1) (41). Because membrane-impermeant 
starch-desferal is specifically taken up via endocytosis into the 
lysosomal/endosomal compartment, protection by starch-desferal against APAP-
induced cell killing implies that endosomes/lysosomes are the source of 
mobilizable chelatable iron during APAP hepatotoxicity. Ru360 and minocycline 
are MCFU inhibitors and protect cells from chemical hypoxia and I/R injury (107, 
108). They also prevented APAP-induced cell killing by half at 6 h, suggesting 
that uptake of Fe2+ into mitochondria via MCFU contributed to APAP 
hepatotoxicity (Fig 3-1). Accordingly, the goals of this study were to characterize 
pathways of chelatable iron movement and identify whether blockade of iron 
mobilization protects against APAP toxicity to mouse hepatocytes. 
 
To visualize iron mobilization in hepatocytes during APAP hepatotoxicity, I 
used confocal microscopy of cytosolic calcein and a newly developed 
mitochondrial iron indicator, MFF (112, 115). Quenching of green calcein 
fluorescence is specific for cytosolic chelatable Fe2+ (41), whereas cationic MFF 
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accumulates electrophoretically into mitochondria and then binds covalently 
proteins via a halomethyl residue. Hence, quenching of red MFF fluorescence is 
specific for mitochondrial chelatable Fe2+ (116). After oxidative stress and 
ischemia-reperfusion injury, lysosomes (and/or endosomes) release iron into the 
cytosol, which then translocates into mitochondria (53, 117). Here after APAP, 
cytosolic calcein and mitochondrial MFF fluorescence began to quench at 4 h, 
indicating increases of chelatable Fe2+ in both cytosol and mitochondria. This 
time point is also associated with maximal GSH depletion after APAP (39), 
consistent with the conclusion that GSH depletion precedes lysosomal Fe2+ 
release and translocation into mitochondria.  
 
Accumulation of iron in the cytosol and iron uptake into mitochondria then 
occurred progressively until the abrupt onset of mitochondrial depolarization after 
~10 h (Fig. 3-2, 3-3). Gradual, progressive lysosome breakdown or lysosomal 
release of iron by a second controlled pathway might explain the kinetics of iron 
release. For example, divalent metal transporter 1 (DMT-1) and transient 
receptor potential mucolipin subfamily member 1 (TRPML1) are iron transporters 
in lysosomal membranes (118, 119). Further studies will be needed to determine 
the role of DMT-1 and TRPML1 in lysosomal iron release during APAP 
hepatotoxicity.  
 
MCFU is the principal transporter for iron entry into mitochondria during 
oxidative stress, chemical hypoxia and ischemia-reperfusion (IR)-induced 
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hepatocellular injury (53, 108, 117). Here, MCFU inhibitors, Ru360 and 
minocycline, suppressed mitochondrial MFF quenching but not cytosolic calcein 
quenching after APAP (Fig. 3-7), indicating that MCFU is also a principal 
pathway for chelatable iron uptake into mitochondria during APAP hepatotoxicity. 
However MCFU also transports Ca2+ into mitochondria, which may also have an 
important role in chemical hypoxia and I/R injury (108). Nonetheless because 
starch-desferal, chelates Fe2+ but not Ca2+ and because Fe2+ but not Ca2+ 
quenches calcein and MFF, mitochondrial iron rather than Ca2+ seems likely to 
the primary instigator in APAP-induced mitochondrial dysfunction. Nonetheless, I 
cannot exclude a permissive role of Ca2+ in APAP-induced injury.  
 
After APAP, mitochondrial generation of ROS is a critical factor triggering 
the MPT, and agents that inhibit ROS formation protect against APAP 
hepatotoxicity (38, 114, 120). OH•-, whose formation is catalyzed by iron via the 
Fenton reaction (121), is a particularly toxic ROS that damages DNA, protein and 
membranes (122). In this study, APAP induced increase of mitochondrial ROS 
formation, represented by increase of MitoSox Red fluorescence (Fig. 3-10). 
Starch-desferal, Ru360 and minocycline inhibited mitochondrial ROS generation 
substantially, indicating the critical role of mitochondrial iron loading in APAP-
induced ROS formation (Fig. 3-11). However, cmDCF fluorescence in total cells 
increased to a larger extent than MitoSox Red fluorescence in mitochondria after 
APAP exposure, suggesting that some ROS generation may also occur in the 
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cytosol (Fig. 3-12). Alternatively, the MitoSox Red signal may have become 
saturated due to consumption of the probe by reaction with O2•
-.  
 
My findings support a “two hit” hypothesis of the role of oxidative stress and 
iron in APAP hepatotoxicity (Fig. 3-14). In the first hit, NAPQI generated by APAP 
metabolism induces mitochondrial protein adduct formation, disrupting 
mitochondrial respiration and leading to generation of O2•
- and H2O2. In the 
second hit, toxic NAPQI causes lysosomal damage and release of chelatable 
Fe2+ into the cytosol. Fe2+ is then taken up into mitochondria via MCFU. Such 
mitochondiral Fe2+ loading induces OH• formation via Fenton reaction, which in 
turn causes MPT onset and mitochondria depolarization. My results indicate that 
blocking this specific route of Fe2+ mobilization into mitochondria with the iron 
chelator, starch-desferal, and the MCFU inhibitors, Ru360 and minocycline, 
protect against APAP-induced hepatic injury. Interestingly, minocycline treatment 
1 h after APAP also shows protection effect, suggesting its potential therapeutic 
benefit in the clinic (Fig. 3-13). Future studies will be needed to place other hits, 
such as activation of JNK, in this overall chain of causation in APAP 
hepatotoxicity (see Chapter 2)  
 
In conclusion, iron mobilization from damaged lysosomes into mitochondria 
via MCFU mediates APAP-induced hepatocellular injury. Increased mitochondrial 
O2•
-/H2O2 generation and chelatable iron after NAPQI formation promote highly 
toxic OH• generation to cause MPT onset, mitochondrial depolarization and cell 
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death. Chelating iron with starch-desferal and blocking iron uptake into 
mitochondria with Ru360 and minocycline protect against injury. Since 
minocycline is an FDA-approved drug, future studies will focus on optimizing 




































Figure 3-1. APAP-induced necrotic cell killing in mouse hepatocytes: 
protection by starch-desferal, Ru360 and minocycline. Mouse hepatocytes 
were exposed to 10 mM APAP. Some cells were treated with 1 mM starch-
desferal, 100 nM Ru360, 4 µM minocycline or no addition 1 h before APAP. Cell 
viability was determined via PI fluorimetry. Control represents hepatocytes 
unexposed to APAP. Values are means ± SE from three or more hepatocyte 








Figure 3-2. Cytosolic calcein quenching after APAP. Hepatocytes were 
exposed to 10 mM APAP in the presence of 20 mM fructose plus 5 mM glycine to 
prevent cell death after APAP-induced disruption of mitochondrial metabolism. 
After 1.5 h of treatment with APAP or no addition, cells were loaded with 500 nM 
TMRM, 1 µM calcein-AM and 3 µM PI in HDM and then incubated in the 
presence of 300 µM calcein-free acid for confocal imaging, as described in 
Materials and Methods. After 12 h, 20 mM DPD was added. Lastly, 375 µM 
digitonin (Dig) was added to permeabilize plasma membranes. Arrows, PI-





Figure 3-3. Mitochondrial MFF quenching after APAP. Hepatocytes were 
exposed to 10 mM APAP in the presence of fructose plus glycine, as described 
in Fig. 3-2. After 1.5 h of treatment with APAP (B) or no addition (A), cells were 
loaded with 500 nM Rh123 and 1 µM MFF for confocal imaging, as described in 
Materials and Methods. After 12 h, 20 mM DPD was added. Lastly, 375 µM 
digitonin (Dig) and 3 µM PI were added to induce plasma membrane 












Figure 3-4. Inhibition of APAP-induced quenching of cytosolic calcein by 
starch-desferal. Hepatocytes were preincubated with 1 mM starch-desferal 1 h 
before APAP. Afterwards, hepatocytes were exposed to APAP as described in 
Fig. 3-2. After 1.5 h, cells were loaded with TMRM, calcein-AM and PI in HDM 
and then incubated in the presence of calcein-free acid for confocal imaging, as 








Figure 3-5. Ru360 and minocycline do not inhibit APAP-induced quenching 
of cytosolic calcein. Hepatocytes were preincubated with 100 nM Ru360 or 4 
µM minocycline 1 h before APAP. Afterwards, hepatocytes were exposed to 
APAP as described in Fig. 3-2. After 1.5 h, cells were loaded with TMRM, 
calcein-AM and PI in HDM and then incubated in the presence of calcein-free 









Figure 3-6. Suppression of quenching of cytosolic calcein fluorescence by 
starch-desferal but not Ru360 or minocycline. Average calcein fluorescence 
of individual hepatocytes after background subtraction was quantified 2-10 h after 
treatment with APAP as the percentage of fluorescence at 2 h. Hepatocytes were 
treated with starch-desferal, Ru360, minocycline, or APAP alone, as described in 
Fig. 3.3, 3.4 and 3.5. Values are means ± SE from three or more hepatocyte 
isolations. *, P< 0.01 vs other groups. 
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Figure 3-7. Prevention of APAP-induced quenching of mitochondrial MFF 
by Ru360 and minocycline. Hepatocytes were preincubated with 100 nM 
Ru360 or 4 µM minocyline 1 h before APAP. Subsequently, the hepatocytes 
were exposed to APAP, as described in Fig. 3-2. After 1.5 h, cells were loaded 
with 500 nM Rh123 and 1 µM MFF in HDM for confocal imaging, as described in 










Figure 3-8. Prevention of APAP-induced quenching of mitochondrial MFF 
by starch-desferal. Hepatocytes were preincubated with 1 mM starch-desferal 1 
h before APAP. Then hepatocytes were exposed to APAP as described in Fig. 3-
2. After 1.5 h, cells were loaded with 500 nM Rh123 and 1 µM MFF in HDM for 







Figure 3-9. Inhibition of APAP-induced MFF quenching and mitochondrial 
depolarization by starch-desferal, Ru360 and minocycline. Average 
mitochondrial Rh123 and MFF fluorescence of individual hepatocytes after 
background subtraction was quantified at 2-10 h as the percentage of 
fluorescence after 2 h. Values are means ± SE from three or more hepatocyte 
isolations. *, P< 0.01 vs other groups. †, P<0.01 vs APAP plus minocycline. 
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Figure 3-10. Inhibition of mitochondrial ROS generation after APAP by 
starch-desferal, Ru360 and minocycline. Hepatocytes were exposed to APAP 
as described for Fig. 3-2. After 3.5 h, cells were loaded with 1 µM MitoSox Red in 









Figure 3-11. APAP induced mitochondrial ROS generation, inhibited by 
starch-desferal, Ru360 and minocycline. Average MitoSox Red fluorescence 
of individual hepatocytes after background subtraction was quantified at 4-10 h 
as the percentage of fluorescence increase after 4 h. Values are means ± SE 
from three or more hepatocyte isolations. *, P< 0.01 vs other groups. 
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Figure 3-12. Protection by starch-desferal, Ru360 and minocycline against 
ROS generation after APAP. Hepatocytes were exposed to APAP as described 
for Fig. 3-2. Some cells were pretreated with starch-desferal, Ru360 or 
minocycline 1 h before APAP. cmH2DCF-DA (10 µM) was added at 1.5 h after 
APAP and cmDCF formation was measured with a plate reader. Average cmDCF 
fluorescence of each well was quantified at 2-10 h as the percentage of 
fluorescence increase after 2 h. Values are means ± SE from three or more 
hepatocyte isolations. *, P< 0.01 vs other groups.  
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Figure 3-13. Posttreatment with minocycline at 1 h after APAP decreases 
killing of mouse hepatocytes. Mouse hepatocytes were exposed to 10 mM 
APAP and treated with 4 µM minocycline or no addition after 1 h. Cell viability 
was determined via PI fluorimetry. Control represents hepatocytes not exposed 
to APAP. Values are means ± SE from three or more hepatocyte isolations. *, 
P<0.01 vs other groups. 
  
Time (h)





























Figure 3-14. Two-hit model of oxidative stress in APAP hepatotoxicity. After 
excess NAPQI following an overdose of APAP, O2•
- and H2O2 formation caused 
by inhibition of mitochondrial respiration represents a first hit predisposing to 
injury. The second hit occurs when lysosomes damaged by NAPQI release Fe2+ 
into the cytosol, which is then taken up into mitochondria via the electrogenic 
mitochondrial Ca2+,Fe2+ uniporter (MCFU) to promote intramitochondrial hydroxyl 
radical (OH•) formation by the Fenton reaction. OH• in turn induces MPT onset 
and mitochondrial depolarization. Starch-desferal chelates lysosomal iron and 
prevents OH• formation. Ru360 and minocycline block mitochondrial iron uptake 
via MCFU and also suppress iron-catalyzed OH• formation in the mitochondrial 











Minocycline and Starch-Desferal Attenuate Liver Injury 
In Vivo after Acetaminophen Overdose in Mice through 







Acetaminophen (APAP) overdose causes hepatotoxicity involving 
mitochondrial dysfunction and the mitochondrial permeability transition (MPT). 
Formation of reactive oxygen species (ROS) increases after APAP exposure and 
triggers the MPT. Iron is a catalyst for ROS formation. Previous studies have 
shown that iron translocation from lysosomes into mitochondria by the 
mitochondrial Ca2+ Fe2+ uniporter (MCFU) promotes the MPT after APAP. 
Starch-desferal is an iron chelator. Minocycline inhibits MCFU. N-acetylcysteine 
(NAC) is a glutathione (GSH) precursor used to treat patients after APAP 
overdose but which loses therapeutic effect in mice when given more than 2 h 
after overdose. Here, my Aim was to assess protection by iron chelation and 
MCFU inhibition against APAP hepatotoxicity in mice. Mouse hepatocytes and 
C57BL/6 mice were administered toxic doses of APAP with and without starch-
desferal, minocycline, or NAC. In hepatocytes, loss of cell viability was 
determined by propidium iodide (PI) fluorimetry. In mice, ALT and necrosis were 
assessed 24 h after APAP. Mitochondrial polarization and cell death were 
assessed by intravital multiphoton microscopy of rhodamine 123 (Rh123) and PI. 
In mice, starch-desferal and minocycline pretreatment decreased serum ALT and 
liver necrosis after APAP by more than 60% (P<0.05). At 24 h after APAP, loss of 
mitochondrial Rh123 fluorescence occurred in pericentral hepatocytes often 
accompanied by PI labeling, indicating mitochondrial depolarization and cell 
death. Starch-desferal and minocycline pretreatment decreased this 
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mitochondrial depolarization and cell death by more than half. In cultured 
hepatocytes, cell killing at 10 h after APAP decreased from 83% to 49%, 35% 
and 27% by 1 h posttreatment with minocycline, NAC, and minocycline plus NAC 
, respectively. Posttreatment of either minocycline or NAC in vivo at 2 h and 3 h 
after APAP overdose also decreased ALT and liver necrosis. With 4 h 
posttreatment, minocycline and minocycline decreased ALT and necrosis by 
~50%, but NAC alone was no longer effective. Seven day survival was 19% and 
28%, respectively, after 4 h posttreatment of vehicle and NAC, which increased 
to 55% after minocycline and 100% after combined minocycline and NAC 
treatment. In conclusion, APAP overdose causes hepatic mitochondrial 
dysfunction and severe liver injury in vivo. Minocycline and starch-desferal 
attenuate these changes, suggesting that the MPT is likely triggered by iron 
uptake into mitochondria through MCFU during APAP hepatotoxicity. Minocycline 
posttreatment after APAP also protects at later time points than NAC, indicating 
that minocycline has longer window of efficacy than NAC. With respect to in vivo 
survival, combined minocycline plus NAC posttreament after APAP overdose 






Acetaminophen (APAP) overdose produces fulminant hepatic necrosis and 
is the leading cause of acute liver failure in North America (123). APAP 
hepatotoxicity is dose-dependent and reproducible in animal models. However 
after more than 40 years of intensive research, the mechanism of APAP-induced 
liver injury is still not fully understood. Important in APAP toxicity is generation by 
cytochrome P450 oxidation of N-acetyl-p-benzoquinoneimine (NAPQI) from 
APAP, which is usually detoxified by glutathione (GSH) (5, 6). However, after 
GSH exhaustion, covalent binding of NAPQI to protein occurs, which promotes 
oxidative stress and onset of the mitochondrial permeability transition (MPT), 
resulting in hepatocellular death (16, 17, 31, 39). 
 
A number of studies have examined the importance of mitochondrial 
dysfunction and oxidative stress in APAP toxicity (124-126). The MPT, an abrupt 
increase in the permeability of the mitochondrial inner membrane to solutes up to 
a molecular mass of about 1500, has emerged as a major mechanism in APAP 
hepatotoxicity (16, 30). The MPT is promoted by oxidative stress, which in turn 
promotes more oxidative stress (127, 128). Iron, which catalyzes hydroxyl radical 
(OH•) formation by Fenton reaction, plays a critical role in oxidative stress in 
injuries to many organs, including liver, heart, kidney and brain (66-68). Fenton 
chemistry may also have an important role in APAP hepatotoxicity (43, 121). 
Iron-catalyzed OH• formation (Fenton chemistry) is initiated by O2•
- formation and 
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dismutation to H2O2. H2O2 further reacts with Fe
2+ to yield OH• and Fe3+. 
Subsequent reaction of Fe3+ with O2•
- then regenerates Fe2+ to continue the 
reaction. Previously, we identified lysosomes/endosomes, which rupture after 
APAP treatment, as the source of mobilizable chelatable iron in APAP 
hepatotoxicity (41, 53, 106). This Fe2+ which is released into the cytosol is then 
taken up into mitochondria via the electrogenic mitochondrial Ca2+,Fe2+ uniporter 
(MCFU) to promote intramitochondrial OH• formation by the Fenton reaction, 
which in turn causes MPT onset and mitochondrial depolarization (Chapter 3).  
 
Previous studies show that the iron chelator, desferal, decreases APAP-
induced hepatotoxicity (41, 71). Starch-desferal is synthesized by covalently 
attaching desferal to a modified starch polymer. This high-molecular-weight 
chelator retains the affinity and specificity of desferal for iron. Starch-desferal has 
prolonged vascular retention and greatly reduced acute toxicity as compared with 
an equivalent dose of desferal. Starch-desferal is taken up into cells by 
endocytosis and localizes into the lysosomal/endosomal compartment. Starch-
desferal, also prevents mitochondrial depolarization and protects hepatocytes 
against cell death after APAP (41). However, the effect of starch-desferal on 
APAP-induced hepatotoxicity in vivo is not known. 
 
MCFU transports Fe2+ into mitochondria during oxidative injury to 
hepatocytes (53, 61). Minocycline is a semisynthetic tetracycline antibiotic that 
protects against neurodegenerative disease, trauma and ischemia/reperfusion 
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injury (25, 129-135).  Recent studies show that minocycline blocks Fe2+ uptake 
via MCFU, suggesting that protection might be by preventing mitochondrial Fe2+ 
uptake (108, 109). The glutathione (GSH) precursor N-acetylcysteine (NAC) is 
used to treat patients with APAP overdose. However, protection becomes 
ineffective when NAC is given later than 2 h after APAP overdose in animal 
studies (90). Here, I show that minocycline and starch-desferal protect against 
mitochondrial dysfunction and hepatic injury after APAP and compared the 
effects of minocycline with those of starch-desferal, a lysosomal iron chelator, in 
a mouse model. I show further that therapeutic post-treatment with minocycline is 






Materials and Methods 
 
Materials 
Starch-desferal was from the generous gift of Biomedical Frontiers 
(Minneapolis, MN). Minocycline, tetracycline, N-acetylcysteine (NAC), rhodamine 
123 (Rh123), propidium iodide (PI), and other reagents were purchased from 
Sigma-Aldrich (St. Louis, MO). 
 
Animals  
Male C57BL/6 mice (8-9 weeks) were housed in an environmentally 
controlled room with a 12-hour light/dark cycle and free access to food and 
water. After overnight fasting, mice were treated with vehicle (warm saline) or 
APAP (300 or 600 mg/kg, i.p.). Starch-desferal (100 mg/kg), minocycline (10 
mg/kg), NAC (300 mg/kg) and vehicle (warm saline) were administrated (i.p.) 1 h 
before or 2, 3, or 4 h after APAP (i.p.). Animal protocols were approved by the 
Institutional Animal Care and Use Committee. 
 
Isolation and Culture of Mouse Hepatocytes  
Hepatocytes were isolated from 20 to 25 g overnight-fasted male C57BL/6 
mice (Jackson Laboratory, Bar Harbor, ME) by collagenase perfusion through the 
inferior vena cava, as described previously (53). Hepatocytes were resuspended 
in Waymouth’s medium MB-752/1 supplemented with 2mM L-glutamine, 10% 
fetal calf serum, 100nM insulin, 100nM dexamethasone, 100 U/ml penicillin, and 
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100 µg/ml streptomycin, as previously described (110). Cell viability was greater 
than 85% by trypan blue exclusion. Hepatocytes were plated on 0.1% type 1 rat 
tail collagen-coated 24-well microtiter plates(1.5 × 105 cells per well). After 
attaching for 3 hours in humidified 5% CO2, 95% air at 37
0C, hepatocytes were 
washed once and placed in hormonally defined medium (HDM) consisting of 
RPMI 1640 (Gibco, Rockville, MD) supplemented with 240 nM insulin, 2 mM L-
glutamine, 1 µg/ml transferrin, 0.3 nM selenium, 100 U/ml penicillin, and 100 
µg/ml streptomycin at pH 7.4.  
 
Fluorimetric Assay of Cell Viability  
Cell death were assessed using a NovoStar multiwell plate reader (BMG 
Lab Technologies, Offenburg, Germany), as previously described (48, 49). 
Briefly, after attachment to 24-well plates for 3 h, hepatocytes were washed once 
and HDM containing 30 µM propidium iodide (PI, Invitrogen, Eugene, OR) was 
added. Hepatocytes were then incubated with 10 mM APAP. In some 
experiments, hepatocytes were treated with 4 µM minocycline and/or 20 mM 
NAC 1 h after APAP. PI fluorescence from each well was measured at excitation 
and emission wavelengths of 544 nm and 620 (40-nm bandpass), respectively. 
For each well, fluorescence was first measured at 20 min after addition of PI 
(Initial) and then at various times after treatment of APAP (X). Experiments were 
terminated by permeabilizing plasma membranes with 375 μM digitonin. After 
another 20 min, a final fluorescence measurement (Final) was collected. The 
percentage of nonviable cells (D) was calculated as D = 100(X -Initial)/(Final - 
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Initial). Cell killing assessed by PI fluorimetry correlates closely with trypan blue 
exclusion and enzyme release as indicators of oncotic necrosis (124, 126). 
 
Alanine aminotransferase 
At 24 hours after vehicle or APAP injection, mice were anesthetized with 
ketamine/xylazine (ketamine 100 mg/kg, xylazine 10 mg/kg, i.p.), and blood was 
collected from the inferior vena cava. Serum alanine aminotransferase (ALT) was 
measured using a commercial kit (Pointe Scientific, Canton, MI). 
 
Histology  
Histology was evaluated at 24 hours after vehicle or APAP injection. Liver 
tissues were fixed by immersion in 4% buffered paraformaldehyde and 
embedded in paraffin. In sections stained with hematoxylin and eosin (H&E), 10 
random fields per slide were assessed for necrosis by standard morphologic 
criteria (e.g., loss of architecture, vacuolization, karyolysis). Images were 
captured in a blinded manner using a Zeiss Axiovert 200M inverted microscope 
(Carl Zeiss, Thornwood, NY) and a 10X objective lens. Necrotic areas were 
quantified by computerized image analysis using IP Lab version 3.7 software (BD 
Biosciences, Rockville, MD) by dividing necrotic areas by total area of the 
images. 
 
Glutathione (GSH) Measurement 
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At 0 to 24 h after APAP or vehicle, mice were euthanized and small pieces 
of liver tissue were quickly dissected and homogenized in lysis buffer at 4. Total 
glutathione (GSH plus GSSH) in liver homogenates was measured with a 
commercial kit (OXIS International, Portland, OR) according to the 
manufacturer’s instructions. 
 
Intravital Multiphoton Microscopy  
At 24 h after vehicle or APAP injection, mice were anesthetized with 
ketamine/xylazine and connected to a small animal ventilator via a respiratory 
tube (20-gauge catheter) inserted into the trachea. Green-fluorescing rhodamine 
123 (Rh123, 2 µmol/mouse, mitochondrial ΔΨ indicator) plus red-fluorescing PI 
(0.4 µmol/mouse, cell death indicator) were infused via polyethylene-10 tubing 
inserted into the femoral vein over 10 min (25, 81, 82). After infusion of these 
fluorescent probes, individual mice were laparotomized and placed in a prone 
position. The liver was gently withdrawn from the abdominal cavity and placed 
over a #1.5 glass coverslip mounted on the stage of an inverted Olympus 
Fluoview 1200 MPE confocal/multiphoton microscope (Olympus, Center Valley, 
PA) equipped with a 60X 1.30 NA silicone oil-immersion objective lens and a 
Spectra Physics Mai Tai Deep Sea tunable multiphoton laser (Newport, Irvine, 
CA). Non-descanned green and red fluorescence were separated using 495-540-
nm and 575-630-nm band pass filters. Rh123 and PI fluorescence was imaged 
simultaneously using 800-nm multiphoton excitation. Unless otherwise stated, 
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images were collected 25 µm from the liver surface. Pericentral areas were 
identified from the sinusoidal configuration under the microscope.  
 
Punctate green Rh123 and red TMRM fluorescence in hepatocytes 
represented polarized mitochondria, whereas dimmer diffuse fluorescence 
signified mitochondrial depolarization (81). Depolarized areas were quantified in 
10 random fields using IP Lab version 3.7 software (BD Biosciences, Rockville, 
MD) by dividing depolarized areas by total area of the images. Nonviable PI-
positive cells, indicated by red nuclear fluorescence, were also counted in ten 
random fields per liver. 
 
Survival Study  
Treatment with vehicle, minocycline, NAC, and minocycline plus NAC was 
performed in a randomized, prospective fashion, and mice were followed 7 days 
after APAP.  
 
Statistics 
Data are presented as means ± SEM. Images shown are representative of 
three or more experiments. Statistical significance was determined by Student t 






Starch-desferal and minocycline decrease acetaminophen-induced ALT 
release and necrosis 
Liver injury after APAP overdose was assessed from ALT release and cell 
necrosis. Control mice had serum ALT of 32 ± 7.3 U/L. When mice were 
administrated with 300 mg/kg APAP, ALT increased to 9041 ± 480 U/L after 24 
(Fig. 4-1), as observed by others (136). After pretreatment with 100 mg/kg 
starch-desferal and 10 mg/kg minocycline 1 h before APAP addition, ALT 
decreased to 3538 ± 737 U/L and 3214 ± 862 U/L at 24 h, respectively (P<0.01). 
Identical treatment with tetracycline did not cause a statistically significant 
change of serum ALT (6860 ± 1060 U/L) compared to vehicle. Histology of 
control livers was normal. By contrast at 24 h after 300 mg/kg APAP, necrotic 
areas increased to 52% with a predominately pericentral distribution, which 
decreased to 22% and 20% by starch-desferal and minocycline, respectively 
(Fig. 4-2) (P<0.05). Overall, starch-desferal and minocycline markedly reduced 
liver injury after APAP.  
  
Minocycline does not alter glutathione depletion after acetaminophen 
To investigate whether minocycline affected the metabolism of APAP, total 
glutathione in liver tissue was measured (Fig. 4-3). Glutathione in control livers 
increased 62%, 32% and 110% after 2, 4, 6 and 24 h, respectively. Increasing 
glutathione was due to refeeding of mice after fasting at the beginning of the 
97 
 
experiment, since fasting causes a decrease of hepatic glutathione (12). 
Minocycline had no effect on this glutathione recovery. After APAP, glutathione 
decreased by 71% and 76% after 2 and 4 h, respectively, and then began to 
recover after 6 h. After 24 h, glutathione had recovered completely and was not 
different from APAP-untreated livers. Minocycline pretreatment did not change 
glutathione depletion and subsequent recovery after APAP treatment. Adduct 
formation between glutathione and NAPQI causes glutathione depletion after 
APAP, and the rate of glutathione depletion parallels that for NAPQI formation (5, 
40, 137). Thus, minocycline did not alter APAP metabolism. 
 
Starch-desferal and minocycline prevent mitochondrial dysfunction and 
cell death in vivo after acetaminophen 
Mitochondria dysfunction is closely related to liver injury. Therefore, we 
explored whether the mitochondrial depolarization occurred after APAP overdose 
using intravital multiphoton microscopy. In control mice, green fluorescence of 
Rh123 was punctate in virtually all hepatocytes, indicating mitochondria 
polarization (Fig. 4-4A). Cytosolic and nuclear areas had little fluorescence. Red 
PI labeling of nuclei, an indicator of cell death, was rare. By contrast at 24 h after 
APAP overdose, Rh123 staining became diffuse and dim in many hepatocytes in 
a predominately pericentral distribution, indicating mitochondrial depolarization 
(Fig. 4-4B, white arrows). Additionally, some nuclei of hepatocytes with 
depolarized mitochondria labeled with the red fluorescence of PI (Fig. 4-4B, 
yellow arrows). Overall, all nonviable cells had depolarized mitochondria. 
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However, many hepatocytes with diffuse and dim Rh123 staining were not yet 
labeled with PI, indicating that mitochondrial depolarization occurs before cell 
death. 
 
After APAP following starch-desferal treatment, most hepatocytes showed 
bright and punctate staining of Rh123, indicating mitochondrial polarization, and 
fewer hepatocytes had depolarized mitochondria (Fig. 4-4C, white arrows, 
compare to 4-4B). PI labeling of nuclei also decreased after starch-desferal 
treatment. Similarly, minocycline treatment decreased mitochondrial 
depolarization and loss of cell viability after APAP (Fig. 4-4D, white arrows). 
However, mitochondrial depolarization and cell death after tetracycline treatment 
were indistinguishable from vehicle-treated mice (data not shown). 
 
At 24 h after APAP, hepatocytes were counted and scored for Rh123 and 
PI labeling (Fig. 4-5). In control livers that were not treated with APAP, virtually 
every hepatocyte contained polarized mitochondria, and PI-labeled nonviable 
cells were absent. At 24 h after APAP, 81% of hepatocytes contained 
depolarized mitochondria, and nonviable hepatocytes were 5.5 ± 1.0 cells/HPF 
(Fig. 4-5). Starch-desferal treatment decreased mitochondrial depolarization and 
nonviable cells to 27% and 0.5 ± 0.3 cells/HPF, respectively (P<0.05). After 
APAP with minocycline treatment, hepatocytes with depolarized mitochondria 
also decreased to 30% and nonviable cells decreased to 0.6 ± 0.3 cells/HPF 
(Fig. 4-5) (P<0.05). Thus, starch-desferal and minocycline conferred similar 
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protection. Because starch-desferal is a lysosomally targeted iron chelator and 
minocycline is an MCFU inhibitor, these results are consistent with the 
conclusion that APAP overdose induces lysosomal iron release and uptake into 
mitochondria in vivo to cause hepatotoxicity. 
 
Minocycline and NAC treatment after acetaminophen decreases cell killing 
in vitro 
To test the therapeutic effect of minocycline against APAP hepatotoxicity 
compared to NAC, mouse hepatocytes were post-treated 1 h after 10 mM APAP 
with minocycline, NAC, and minocycline plus NAC. Cell killing was determined by 
PI fluorimetry. After APAP, hepatocytes progressively lost viability, leading to 
83% cell death at 10 h. Post-treatment at 1 h with minocycline or NAC 
individually attenuated cell killing to 49% and 37% at 10 h, respectively (Fig. 4-6). 
The combination of minocycline and NAC decreased cell killing to 27%, which 
was statistically significant compared to minocycline alone (P<0.05) but not to 
NAC alone (P=0.14). 
 
Protection by minocycline and NAC against acetaminophen-induced liver 
injury in vivo  
To assess protection in vivo by minocycline in comparison to NAC against 
APAP-induced liver injury, mice were treated with minocycline (10 mg/kg) and 
NAC (300 mg/kg) at 2, 3 and 4 h after APAP. Two hour post-treatment with 
minocycline, NAC and minocycline plus NAC decreased serum ALT at 24 h after 
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APAP by 62%, 76% and 84%, compared to APAP plus vehicle (Fig. 4-7). When 
minocycline, NAC and minocycline plus NAC were treated 3 h after APAP, serum 
ALT was decreased by 58%, 54% and 66%, respectively. However, when mice 
were treated with these drugs 4 h after APAP, NAC lost its protection, but 
minocycline still showed protection by decreasing ALT by 21%. Interestingly, 
minocycline plus NAC treatment decreased ALT by 42%, indicating better 
protection than either minocycline or NAC alone (P<0.05).  
 
Liver injury was also assessed histologically at 24 h after APAP. Overdose 
APAP induced 53% liver necrosis at 24 h (Fig. 4-8). Post-treatment 2 h after 
APAP with minocycline, NAC and minocycline plus NAC decreased necrosis to 
20%, 21% and 17%, respectively. Post-treatment at 3 h with minocycline, NAC 
and minocycline plus NAC still decreased necrosis but to a smaller extent. 
However after post-treatment at 4 h, NAC failed to decrease necrosis, whereas 
minocycline and minocycline plus NAC decreased necrosis to 37% and 25%, 
respectively. These results indicated that NAC alone was not effective in 
preventing hepatotoxicity at 4 h following APAP, but minocycline and minocycline 
plus NAC given 4 h after APAP still showed protection. Again, minocycline plus 
NAC treatment showed better protection than either minocycline or NAC alone 
(P<0.05). 
 




To investigate survival after APAP overdose, I increased the dose of APAP 
to 600 mg/kg followed by 4 hour-post-treatment with vehicle, minocycline, NAC 
and minocycline plus NAC. Survival to 7 days was less than 20% after APAP 
plus vehicle (Fig. 4-9). NAC alone did not cause a statistically significant 
improvement of survival, whereas minocycline alone improved survival 
significantly to 57%. Remarkably, post-treatment at 4 h with minocycline plus 






Much evidence for a role of iron in APAP toxicity has been published 
previously. The iron chelator, desferal, protects hepatocytes after APAP, 
whereas addition of iron back to the incubation restored the sensitivity of 
hepatocytes to APAP (43, 71, 138). In a previous study, the lysosomally targeted 
iron chelator, starch-desferal, also decreases cell killing, indicating that 
lysosomes are a source of mobilizable chelatable iron during APAP 
hepatotoxicity (41). Recently, minocycline was shown to be a mitochondrial Ca2+ 
Fe2+ uniporter (MCFU) inhibitor, which protects hepatocytes from chemical 
hypoxia and I/R injury both in vitro and in vivo (108, 139). Minocycline also 
prevents cell killing and movement of iron into mitochondria after APAP, 
suggesting that uptake of Fe2+ into mitochondria via MCFU is responsible for 
APAP hepatotoxicity (Chapter 3). Here in an in vivo mouse model of APAP 
overdose hepatotoxicity, minocycline pretreatment decreased serum ALT and 
liver necrosis by half. Starch-desferal afforded similar protection, consistent with 
the conclusion that lysosomal disruption and iron mobilization into mitochondria 
also occur in vivo during APAP hepatotoxicity (Fig. 4-1 and 4-2). 
 
The MPT has been identified as a likely mechanism in APAP-induced 
hepatotoxicity (16). Previous studies show that toxic doses of APAP induce 
mitochondrial depolarization and inner membrane permeabilization in cultured 
mouse hepatocytes, which are decreased by the MPT inhibitors, CsA and 
NIM811(16, 31, 41). Intravital multiphoton imaging showed directly that 
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mitochondrial depolarization occurs in vivo in mouse livers after APAP overdose 
(Fig. 4-4B). Similar to previous results that minocycline inhibits MPT onset after 
orthotopic rat liver transplantation and mice hemorrhagic shock (25, 135), I found 
that minocycline and starch-desferal prevented mitochondrial depolarization after 
APAP in the mouse model (Fig. 4-4C, D). These results suggest that the MPT is 
likely triggered by iron uptake into mitochondria through MCFU during APAP 
hepatotoxicity. 
 
Tetracycline is an antibiotic similar to minocycline, but which does not inhibit 
MCFU. In ischemia/reperfusion injury during liver transplantation and 
hemorrhage and resuscitation, tetracycline does not protect against liver injury 
(25, 108, 135). Similarly in the present study, tetracycline did not protect 
significantly against APAP-induced ALT release, liver necrosis and mitochondrial 
depolarization (Fig. 4-1, 4-2), suggesting strongly that minocycline protection 
against APAP hepatotoxicity is mediated by MCFU inhibition. After APAP 
overdose, the rate of glutathione depletion parallels that of NAPQI formation. 
Here, the time course and extent of hepatic glutathione depletion after APAP was 
virtually identical with and without minocycline, indicating that minocycline does 
not inhibit bioactivation of APAP to NAPQI (Fig. 4-3). Thus, the protection against 
liver injury and mitochondrial dysfunction by minocycline is likely due to inhibition 
of iron mobilization into mitochondria via MCFU rather than prevention of APAP 
activation to NAPQI or glutathione depletion. 
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My ultimate goal in this research was to develop new translatable clinical 
strategies to minimize liver injury induced by APAP overdose. The formation of 
NAPQI, which first depletes glutathione and subsequently causes protein adduct 
formation, is a critical event in the APAP hepatotoxicity (14). N-acetylcysteine 
(NAC) is a glutathione precursor, which promotes hepatic glutathione synthesis 
and supports the detoxification of NAPQI (140, 141). Accordingly, the glutathione 
precursor NAC was introduced to treat patients with APAP overdose in the 1970s 
and remains the preferred therapeutic option for APAP overdose patients. NAC is 
most effective when given as early as possible after APAP intoxication, and 
therapeutic efficacy decreases when NAC is administered more than 8 h after 
APAP poisoning (142). In mice, protection is lost when NAC is given later than 2 
h after APAP overdose (143, 144). Previously, an important role of iron in APAP 
toxicity was shown by the observation that the iron chelator, desferal, 
administrated to mice 1 h after APAP decreased hepatotoxicity without altering 
covalent adduct formation (71). Here, I compared individual post-treatments with 
minocycline and NAC against APAP-induced liver injury. Minocycline and NAC 
post-treatment 2 and 3 h after APAP both decreased ALT release and liver 
necrosis, but NAC post-treatment 4 hours after APAP failed to protect, whereas 
minocycline provided some protection (Fig. 4-7 and 4-8). However with 4 h post-
treatment, the combination of minocycline plus NAC provided better protection 
against liver necrosis than minocycline or NAC alone. Minocycline 4 h-post-
treatment also increased 7-day survival after APAP compared to NAC, but 
minocycline plus NAC improved survival even more (Fig. 4-9). These results may 
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be explained by the different principles of protection by NAC and minocycline. 
NAC replenishes glutathione depletion after, whereas minocycline prevents iron 
translocation into mitochondria. In cultured mouse hepatocytes, glutathione 
depletion is maximal at 2 h after APAP (16). However, lysosomal iron 
mobilization via MCFU occurs beginning after about 4 h of APAP exposure, 
which then promotes the MPT and cell killing (41) (see Chapter 3). Since Fe2+-
dependent MPT is downstream of glutathione depletion after APAP, minocycline 
may prevent liver injury through inhibition of iron mobilization into mitochondria 
via MCFU at later time points after APAP than NAC. Moreover, since minocycline 
and NAC act via different mechanisms, their protection is synergistic. 
 
Interestingly, minocycline plus NAC is more effective than NAC or 
minocycline alone in treatment of APAP hepatotoxicity both in vitro and in vivo 
(Fig. 4-6, 4-7, 4-8). Some time for glutathione re-synthesis is required for NAC to 
be fully effective. By contrast, inhibition of iron movement into mitochondria by 
minocycline should occur immediately upon MCFU blockade, which means 
minocycline provides protection more rapidly than NAC. Alternatively, glutathione 
replenishment by NAC may decrease oxidative stress not related to the iron-
catalyzed Fenton reaction. Accordingly, minocycline plus NAC treatment showed 
better protection than NAC or minocycline alone. 
 
In conclusion, our results indicate that chelatable iron mobilization from 
damaged lysosome into mitochondria via MCFU plays a key role in APAP-
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induced liver injury in vivo. Minocycline is a safe and widely used FDA-approved 
drug. The protection by minocycline post-treatment against APAP hepatotoxicity 
suggests its clinical benefit, especially in combinations with current therapies 










Figure 4-1. Starch-desferal and minocycline decrease ALT release after 
APAP overdose. Mice were administered 300 mg/kg APAP or vehicle. Starch-
desferal (100 mg/kg), minocycline (10 mg/kg), tetracycline (10 mg/kg) or vehicle 
was given 1 h before APAP, as described in Materials and Methods. Serum 
ALT was assessed 24 h after APAP. Values are means ± SE from four or more 











































Figure 4-2. Starch-desferal and minocycline decrease necrosis after APAP. 
Mice were treated with vehicle, starch-desferal, minocycline and/or APAP, as 
described in Fig. 1. Black arrows identify necrotic areas. Area percent of necrosis 
was quantified in liver sections by image analysis of 10 random fields per liver. 











Figure 4-3. Minocycline does not alter APAP-induced glutathione depletion. 
Mice were treated with vehicle, minocycline and/or APAP, as described in Fig. 1. 
After 0 to 24 h of treatment with APAP, liver homogenates were prepared, and 
total glutathione in liver was measured as described in Materials and Methods. 









Figure 4-4. Starch-desferal and minocycline decrease mitochondrial 
depolarization and hepatocellular cell death after APAP. Mice were treated 
with vehicle, starch-desferal or minocycline followed by 300 mg/kg APAP or 
vehicle, as described in Fig. 1. At 24 h after APAP, livers were visualized by 
multiphoton microscopy, as described in Materials and Methods. Shown are 
representative overlay images of green Rh123 and red PI fluorescence collected 
from livers of a control (non-APAP-treated) mouse (A), mouse treated with APAP 
(B), mouse treated with 100 mg/kg starch-desferal 1 h before APAP (C), and 
mouse treated with 10 mg/kg minocycline 1 h before APAP (D). Punctate labeling 
of Rh123 signifies mitochondrial polarization, whereas diffuse, dim cellular 
staining denotes mitochondrial depolarization (white arrows). Nuclear PI labeling 






Figure 4-5. Protection by starch-desferal and minocycline against 
depolarization and cell death induced by APAP. Mice were treated with 
vehicle, starch-desferal or minocycline followed by APAP, as described in Fig.1. 
The average percentage of hepatocytes with depolarized mitochondria is plotted 
for various treatment groups from 10 random fields for 3-4 livers per group (A). 










Figure 4-6. Protection by minocycline and NAC post-treatment 1 h after 
APAP against hepatocyte killing in vitro. Mouse hepatocytes were exposed to 
10 mM APAP and treated with 4 µM minocycline, 20 mM NAC, 4 µM minocycline 
plus 20 mM NAC or no addition after 1 h. Cell viability was determined via PI 
fluorometry. Control represents hepatocytes unexposed to APAP. Values are 
means ± SE from three or more hepatocyte isolations. *, P<0.01 vs other groups; 









Figure 4-7. Protection by post-treatment with minocycline and NAC against 
APAP-induced ALT release in vivo. Mice were administered 300 mg/kg APAP 
or vehicle. Vehicle, minocycline (10 mg/kg) and/or NAC (300 mg/kg) were given 
at 2, 3 and 4 h after APAP, as described in Materials and Methods. Serum ALT 
was assessed 24 h after APAP. Values are means ± SE from four or more mice. 
*, P<0.05 vs vehicle; #, P<0.05 vs NAC alone; @, P<0.05 vs minocycline alone 









Figure 4-8. Protection by post-treatment with minocycline against APAP-
induced hepatic necrosis. Mice were administered 300 mg/kg APAP or vehicle. 
Vehicle, minocycline (10 mg/kg) and/or NAC (300 mg/kg) were administered 2, 3, 
4 h after APAP, as described in Materials and Methods. Liver necrosis was 
assessed 24 h after APAP. Values are means ± SE from four or more mice. *, 










Figure 4-9. Improved survival after APAP overdose by post-treatment with 
minocycline and minocycline plus NAC. Seven-day survival was assessed in 
mice treated with vehicle, minocycline, NAC and minocycline plus NAC at 4 h 
after 600 mg/kg APAP, as described in Materials and Methods. Size of vehicle, 
minocycline and NAC groups was 17. Size of minocycline plus NAC group was 8. 
















Overdose of acetaminophen (APAP) causes severe liver injury, including 
serum alanine aminotransferase (ALT) elevation, hepatic necrosis, and even 
acute liver failure and death. APAP is a threshold hepatotoxicant. Low 
therapeutic doses are completely non-toxic but above a certain dosage liver 
injury occurs. However, the safe upper limit of APAP for patients remains 
controversial. The underlying mechanism of APAP hepatotoxicity involves 
mitochondrial dysfunction, including respiratory inhibition, decreased hepatic 
ATP, decreased mitochondrial membrane potential (ΔΨ) and onset of the 
mitochondrial permeability transition (MPT) (16, 17, 31). Oxidative stress is a 
principal mediator of toxicity and has been suggested as an important 
mechanism in APAP-induced hepatotoxicity (39, 43). Reactive oxygen species 
(ROS) formation occurs selectively in mitochondria after the initial metabolism of 
APAP rather than in cytosol after mitochondrial NAPQI-protein adduct formation 
(39, 40, 145-147). ROS formed in mitochondria include O2•
- and its dismutation 
product, H2O2. Mitochondrial uptake of iron aggravates and enhances ROS-
induced injury due to the Fenton reaction (also called iron-catalyzed Haber-
Weiss reaction) (69, 138). In Fenton chemistry, Fe2+ reduces H2O2 to form Fe
3+ 
and highly reactive OH•. OH• in turn leads to lipid peroxidation and DNA damage. 
Fe2+ then regenerates from Fe3+ by reaction with O2•
-, and the reaction 
continues. Previous studies identified the lysosomal/endosomal compartment as 
a source of mobilizable chelatable iron after APAP and oxidative stress (53, 106). 
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Release of iron from disrupted lysosomes occurs after APAP, which is prevented 
by the iron chelator, desferal (41). 
 
My study further elucidates mitochondrial mechanisms of APAP 
hepatotoxicity and their relationship to iron-induced oxidative stress (Fig. 3-14). I 
demonstrated that low dose APAP can produce reversible mitochondrial 
dysfunction in hepatocytes without causing ALT release or necrosis in vivo and 
that the MPT is the likely underlying principal mechanism (Fig. 2-1 – 2-8). I then 
showed that iron released into the cytosol from damaged lysosomes entered 
mitochondria via the electrogenic MCFU to promote intramitochondrial ROS 
formation by the Fenton reaction, which in turn causes MPT onset and 
mitochondrial depolarization. Blocking release of iron from lysosomes by iron 
chelation (starch-desferal) and iron uptake into mitochondria by MCFU inhibition 
(minocycline and Ru360) prevented ROS formation and APAP-induced injury to 
cultured hepatocytes (Fig. 3-1, 3-11, and 3-12). I next showed that translocation 
of iron from lysosomes into mitochondria also triggered mitochondrial dysfunction 
in APAP hepatotoxicity in vivo, which was also prevented by starch-desferal and 
the MCFU inhibitor, minocycline (Fig. 4-5). Since the Fe2+-dependent MPT is 
downstream of glutathione depletion, I compared the protective effect of 
minocycline with the glutathione precursor, NAC, to show that minocycline can 
protect at a later time point after APAP than NAC, indicating that minocycline has 
a longer window of efficacy than NAC for treating APAP overdose (Fig. 4-7 and 
4-8). However, the greatest efficacy to treat APAP toxicity in vivo occurred when 
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minocycline and NAC were combined, consistent with the idea the minocycline 
and NAC act on different toxic mechanisms. 
 
Reversible mitochondrial depolarization after low dose APAP 
A recent study showed that reversible mitochondrial depolarization occurs 
within minutes during brain ischemia, which is associated with a cyclosporin A-
sensitive MPT (93). In the current study, mitochondrial depolarization happened 
at 6 h and spontaneously recovered at 24 h after low dose APAP but became 
severe and sustained after high dose APAP, indicating that mitochondrial 
dysfunction can be a reversible event in the liver. Protection by NIM811 
implicates the MPT as the cause of this reversible mitochondrial dysfunction. 
Reversible JNK activation at low dose APAP found in the current study may also 
explain this transient phenomenon of mitochondrial depolarization. However 
further studies will be needed to clarify how transient reversible JNK activation 
occurs after low dose APAP and identify its relationship with the reversible MPT 
and mitochondrial depolarization. 
 
Mitochondrial autophagy (mitophagy) selectively eliminates damaged 
mitochondria and protects against mitochondria damage-induced cell death (148, 
149). Several recent studies have discovered an important role of mitophagy in 
preventing APAP hepatotoxicity (103). Our results suggest that increased 
oxidative stress and mitochondrial protein adduct formation after APAP may be 
an important trigger from mitophagy after APAP. Damaged, depolarized 
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mitochondria may be then removed, which in turn attenuates mitochondrial-
mediated oxidative stress, JNK activation, mitochondrial protein release and cell 
death. However when the rate of mitochondria depolarization becomes greater 
than the rate of removal by mitophagy, hepatocellular necrosis happens. Indeed, 
pharmacological inhibition of autophagy exacerbates APAP toxicity, whereas 
promotion of autophagy inhibits APAP toxicity (103, 150). Further studies are 
needed to clarify the relationship between iron- and MPT-dependent 
mitochondrial depolarization and mitophagy induction. 
 
Mitochondrial iron uptake channels 
Iron uptake into mitochondria induces oxidative stress and mitochondrial 
dysfunction in APAP hepatotoxicity. In order to enter the mitochondrial matrix, 
iron must traverse the outer mitochondrial membrane (OMM) and the inner 
mitochondrial membrane (IMM). Voltage-dependent anion channels (VDACs) are 
a class of porin ion channels located on the OMM and play a key role in 
regulating metabolic and energetic flux across the OMM (151). Additionally, 
VDAC may be an important regulator of divalent cation (e.g., Ca2+, Mg2+) 
transport in and out of the mitochondria (151). It is likely that VDAC mediates iron 
movement across OMM, but further studies are needed to test this hypothesis 
and identify any role in APAP hepatotoxicity. Two mitochondrial transporters, 
MCFU and the two isoforms of mitoferrin (Mfrn1/2), have been characterized to 
transport iron across the IMM (61, 62, 152). In the current study, iron uptake into 
mitochondria was prevented by the MCFU inhibitors, minocycline and Ru360. A 
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recent study shows that Mfrn2 physically interacts with MCFU and appears to be 
a component/regulator of the MCFU complex (153). Further experiments will be 
needed to characterize the specific mechanisms involved in the interaction 
between Mfrn1/2 and MCFU. 
 
Human and clinical experiments 
All the experiments performed in this study were based on primary cultured 
mouse hepatocytes or the in vivo mouse model. Although the mouse is a 
clinically relevant species for studies of APAP hepatotoxicity with similar hepatic 
metabolism to human, the metabolism of APAP in mouse is still not identical 
human. Thus, the major findings from this study will need to be extended and 
validated in human hepatocytes. Exposure of human hepatocytes to APAP 
demonstrated glutathione depletion, protein adduct formation, mitochondrial 
dysfunction and eventually cell necrosis (154). The MPT inhibitor, CsA, and the 
JNK inhibitor, leflunamide, protected from APAP-induced death of human 
hepatocytes (155). However, no studies have examined iron-mediated oxidative 
stress in APAP hepatotoxicity in human hepatocytes. Such human hepatocytes 
experiments are needed to confirm that starch-desferal, minocycline and Ru360 
also decrease APAP-induced necrotic cell killing and mitochondrial 
depolarization in human hepatocytes, indicating that lysosomal iron mobilization 





Although Ru360 is a very specific inhibitor of MCFU and protects against 
APAP-induced cell killing, Ru360 degrades in aqueous solution within a few days 
and thus is unsuitable for clinical use. By contrast, minocycline is already FDA-
approved. Although hepatotoxicity has been reported in association with chronic 
minocycline treatment, virtually there is no toxicity associated with its short term 
use (156). Further studies will focus on optimizing conditions for protection by 
minocycline in human hepatocytes and testing the protection effect of 
minocycline against APAP in a clinical setting. 
 
Significance and conclusion 
To my knowledge, this study is the first to demonstrate that otherwise non-
toxic dosages of APAP induce transient mitochondrial dysfunction and that 
mobilization of iron from lysosomes into mitochondria via MCFU is an important 
underlying mechanism in APAP hepatotoxicity in vivo. Iron uptake into 
mitochondria predisposes to reactive oxygen species formation after APAP 
exposure to cause mitochondrial dysfunction, hepatocellular death and liver 
injury. In addition, the iron chelator, starch-desferal, and the MCFU inhibitor, 
minocycline, protected against APAP-induced injury both in primary mouse 
hepatocytes and in the mouse model. Another novel finding is that minocycline 
protects after APAP overdose at a later time point than NAC, indicating that 
minocycline has longer window of efficacy than NAC, although combined 
minocycline plus NAC was most efficacious to treat APAP over dose. In 
conclusion, this study demonstrated that translocation of iron from lysosomes 
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into mitochondria through MCFU is a crucial event causing mitochondrial 
dysfunction and cell death in APAP hepatotoxicity. Blocking this pathway will lead 
to novel strategies to intervene against liver injury caused by APAP poisoning in 
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